[go: up one dir, main page]

WO2001098269A2 - N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine - Google Patents

N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine Download PDF

Info

Publication number
WO2001098269A2
WO2001098269A2 PCT/US2001/019745 US0119745W WO0198269A2 WO 2001098269 A2 WO2001098269 A2 WO 2001098269A2 US 0119745 W US0119745 W US 0119745W WO 0198269 A2 WO0198269 A2 WO 0198269A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
chr
occurrence
substituted
cycloalkyl
Prior art date
Application number
PCT/US2001/019745
Other languages
English (en)
Other versions
WO2001098269A3 (fr
Inventor
Soo S. Ko
George V. Delucca
John V. Duncia
Joseph B. Santella
Dean A. Wacker
Wenqing Yao
Original Assignee
Bristol-Myers Squibb Pharma Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/598,821 external-priority patent/US6605623B1/en
Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company
Priority to AU2001271357A priority Critical patent/AU2001271357A1/en
Priority to EP01950358A priority patent/EP1363881A2/fr
Priority to JP2002504225A priority patent/JP2004517803A/ja
Priority to CA002413274A priority patent/CA2413274A1/fr
Publication of WO2001098269A2 publication Critical patent/WO2001098269A2/fr
Publication of WO2001098269A3 publication Critical patent/WO2001098269A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Definitions

  • This invention relates generally to modulators of chemokine receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and prevention of inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis .
  • Chemokines are chemotactic cytokines, of molecular weight 6-15 kDa, that are released by a wide variety of cells to attract and activate, among other cell types, macrophages, T and B lymphocytes, eosinophils, basophils and neutrophils (reviewed in Luster, New Eng. J Med. , 338, 436-445 (1998) and Rollins, Blood, 90, 909-928 (1997)).
  • CXC chemokines
  • CC two major classes of chemokines, depending on whether the first two cysteines in the a ino acid sequence are separated by a single amino acid (CXC) or are adjacent (CC) .
  • the CXC chemokines such as interleukin-8 (IL-8) , neutrophil-activating protein-2 (NAP- 2) and melanoma growth stimulatory activity protein (MGSA) are chemotactic primarily for neutrophils and T lymphocytes, whereas the CC chemokines, such as RANTES,
  • MlP-l , MlP-l ⁇ , the monocyte chemotactic proteins (MCP-1, MCP-2, MCP-3, MCP-4, and MCP-5) and the eotaxins (-1,-2, and -3) are chemotactic for, among other cell types, macrophages, T lymphocytes, eosinophils, dendritic cells, and basophils.
  • MCP-1, MCP-2, MCP-3, MCP-4, and MCP-5 are chemotactic for, among other cell types, macrophages, T lymphocytes, eosinophils, dendritic cells, and basophils.
  • chemokines bind to specific cell-surface receptors belonging to the family of G-protein-coupled seven- transmembrane-domain proteins (reviewed in Horuk, Trends Phar . Sci., 15, 159-165 (1994)) which are termed "chemokine receptors.”
  • chemokine receptors On binding their cognate ligands, chemokine receptors transduce an intracellular signal through the associated trimeric G proteins, resulting in, among other responses, a rapid increase in intracellular calcium concentration, changes in cell shape, increased expression of cellular adhesion molecules, degranulation, and promotion of cell migration.
  • chemokine receptors There are at least ten human chemokine receptors that bind or respond to CC chemokines with the following characteristic patterns: CCR-
  • Human CC chemokines such as RANTES and MCP-3, can cause rapid mobilization of calcium via these virally encoded receptors. Receptor expression may be permissive for infection by allowing for the subversion of normal immune system surveillance and response to infection. Additionally, human chemokine receptors, such as CXCR4, CCR2, CCR3 , CCR5 and CCR8 , can act as co- receptors for the infection of mammalian cells by microbes as with, for example, the human immunodeficiency viruses (HIV) .
  • HIV human immunodeficiency viruses
  • Chemokine receptors have been implicated as being important mediators of inflammatory, infectious, and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.
  • the chemokine receptor CCR-3 plays a pivotal role in attracting eosinophils to sites of allergic inflammation and in subsequently activating these cells.
  • the chemokine ligands for CCR-3 induce a rapid increase in intracellular calcium concentration, increased expression of cellular adhesion molecules, cellular degranulation, and the promotion of eosinophil migration. Accordingly, agents which modulate chemokine receptors would be useful in such disorders and diseases.
  • agents which modulate chemokine receptors would also be useful in infectious diseases such as by blocking infection of CCR3 expressing cells by HIV or in preventing the manipulation of immune cellular responses by viruses such as cytomegaloviruses .
  • infectious diseases such as by blocking infection of CCR3 expressing cells by HIV or in preventing the manipulation of immune cellular responses by viruses such as cytomegaloviruses .
  • a substantial body of art has accumulated over the past several decades with respect to substituted piperidines and pyrrolidines . These compounds have implicated in the treatment of a variety of disorders.
  • WO 98/25604 describes spiro-substituted azacycles which are useful as modulators of chemokine receptors :
  • Ri is C ⁇ -Q alkyl, optionally substituted with functional groups such as -NR 6 CONHR 7 , wherein R 6 and R 7 may be phenyl further substituted with hydroxy, alkyl, cyano, halo and haloalkyl .
  • Such spiro compounds are not considered part of the present invention.
  • WO 95/13069 is directed to certain piperidine, pyrrolidine, and hexahydro-lH-azepine compounds of general formula:
  • Z NR 6a or 0.
  • WO 93/06108 discloses pyrrolobenzoxazine derivatives as 5-hydroxytryptamine (5-HT) agonists and antagonists:
  • A is lower alkylene and R 4 may be phenyl optionally substituted with halogen.
  • NPY Neuropeptide Y
  • U.S. Pat. No. 5,668,151 discloses Neuropeptide Y (NPY) antagonists comprising 1, 4-dihydropyridines with a piperidinyl or tetrahydropyridinyl-containing moiety attached to the 3 -position of the 4-phenyl ring:
  • B may be NH, NR 1 , O, or a bond
  • R 7 may be substituted phenyl, benzyl, phenethyl and the like.
  • one object of the present invention is to provide novel agonists or antagonists of CCR-3, or pharmaceutically acceptable salts or prodrugs thereof.
  • E, Z, M, J, K, L, Q, R 1 , R 2 , R 3 , and R 4 are effective modulators of chemokine activity.
  • M is selected from CH 2 , CHR 5 , CHR 13 , CR ⁇ R" anc CR 5 R 13 ;
  • Q is selected from CH 2 , CHR 5 , CHR 13 , CR 13 R13 / ano l CR 5 R 13 ;
  • J and L are independently selected from CH 2 , CHR 5 , CHR 6 , CR 6 R 6 and CR 5 R 6 ;
  • K is selected from CHR 5 and CR 5 R 6 ;
  • Z is selected from 0 and S;
  • E is -(CHR 7 )-(CHR 9 ) V -(CR 1:L R 12 )-;
  • R 1 and R 2 are independently selected from H, C ⁇ _s alkyl, C 3 _e alkenyl, C 3 - 8 alkynyl, (CH 2 ) r c 3 -6 cycloalkyl, and a (CH 2 ) r -C 3 - ⁇ o carbocyclic residue substituted with 0-5 R a ;
  • R b at each occurrence, is selected from H, C ⁇ -Q alkyl, C 3 - 6 cycloalkyl, and phenyl;
  • R c at each occurrence, is selected from Ci-g alkyl, C 3 - 6 cycloalkyl, and phenyl;
  • R 2 and R 3 join to form a 5, 6, or 7-membered ring substituted with 0-3 R a ;
  • R 3 is selected from a (CR 3 'R 3 ") r -C 3 _ ⁇ o carbocyclic residue substituted with 0-5 R 15 and a (CR 3 'R 3 ") r -5-10 membered heterocyclic system containing 1-4 heteroato s selected from N, 0, and S, substituted with 0-3 R 15 ;
  • R 3 ' and R 3 ", at each occurrence, are selected from H, C ⁇ - ⁇ alkyl, (CH 2 ) r C 3 _ 6 cycloalkyl, and phenyl;
  • R 4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C ⁇ _s alkyl, C 3 _ 8 alkenyl, C 3 _s alkynyl, (CH 2 ) r C 3 - 6 cycloalkyl, (CH 2 ) q C (0)R 4b , (CH 2 ) q C (0)NR 4a R 4a ' , (CH 2 ) q C(0)OR 4b , and a (CH 2 ) r -C 3 - ⁇ o carbocyclic residue substituted with 0-3 R 4c ;
  • R 4a and R a ' are selected from H, C ⁇ - 6 alkyl, (CH 2 ) r c 3 - 6 cycloalkyl, and phenyl;
  • R 4b at each occurrence, is selected from C - ⁇ alkyl, C 3 .- 8 alkenyl, (CH 2 ) r 3 - 6 cycloalkyl, C 3 - 8 alkynyl, and phenyl ;
  • R 4c is selected from C ⁇ - ⁇ alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, C 3 - 6 cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, (CH 2 ) r OH, (CH 2 ) r SCi_ 5 alkyl, (CH 2 ) r NR a R a ' , and (CH 2 ) r phenyl ;
  • R 4 joins with R 7 , R 9 , or R 11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 R a ;
  • R 5 is selected from a (CR 5 'R 5 ") t _ C 3 - ⁇ o carbocyclic residue substituted with 0-5 R 16 and a (CR 5 'R 5 ") t -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 16 ;
  • R 5 and R 5 ", at each occurrence, are selected from H, C ⁇ _ 6 alkyl, (CH 2 ) r C 3 _ 6 cycloalkyl, and phenyl;
  • R 6 at each occurrence, is selected from C -Q alkyl, C 2 -s alkenyl, C 2 _ 8 alkynyl, (CH 2 ) r C3-6 cycloalkyl, (CF 2 ) r CF 3 , CN, (CH 2 ) r NR 6a R 6a ', (CH 2 ) r OH, (CH 2 ) r 0R 6b , (CH 2 ) r SH, (CH 2 ) r SR 6 , (CH 2 ) r C(0)OH, (CH 2 ) r C (0) R 6 , (CH 2 ) r C(0)NR 6a R 6a ', (CH ) r NR 6d C(0)R 6a , (CH 2 ) r C (0)
  • R ⁇ a and R 6 ' are selected from H, - ⁇ alkyl, C 3 -- 6 cycloalkyl, and phenyl substituted with 0-3 R 6c.
  • R 6b at each occurrence, is selected from C ⁇ _ 6 alkyl, C 3 _g cycloalkyl, and phenyl substituted with 0-3 R 6c ;
  • R 6c is selected from C -Q alkyl, C 3 - S cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, (CH 2 ) r 0H, (CH 2 ) r SC ⁇ _ 5 alkyl, and (CH 2 ) r NR 6d R 6d ;
  • R 6d at each occurrence, is selected from H, ⁇ -Q alkyl, and C 3 - 6 cycloalkyl;
  • R 7 at each occurrence is selected from H or alternatively R 7 joins with R 4 to form a 5, 6, or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3R a ;
  • R 9 at each occurrence is selected from H or alternatively R 9 joins with R 4 to form a 5, 6, or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3R ;
  • R 11 and R 12 join to form a C 3 _ 6 cycloalkyl or a heterocycle selected from pyrrolidine, tetrahydrofuran, piperidine and tetrahydropyran;
  • R 13 is selected from C ⁇ s alkyl, C 2 - 8 alkenyl, C 2 _s alkynyl, C 3 - 6 cycloalkyl, (CF 2 ) W CF 3 , (CH 2 ) g NR 13a R 1 3a' / (CH 2 ) g OH, (CH 2 ) g OR 13b , (CH 2 ) g SH, (CH 2 ) g SR 13b , (CH 2 ) w C(0)OH, (CH 2 ) W C (O) R 13b , (CH 2 ) w C(0)NR 13a R 13a ', (CH 2 ) q NR 13d C(0)R 13 , (CH 2 ) w C(0)OR 13 , (CH 2 ) g 0C(0)R 13b , (CH 2 ) W S (0) p R 13b ,
  • R 13a and R 13 ' are selected from H, ⁇ -Q alkyl, C 3 - 6 cycloalkyl, and phenyl substituted with 0-3 R 13c.
  • R 13b at each occurrence, is selected from C ⁇ _ 6 alkyl, C 3 - 6 cycloalkyl, and phenyl substituted with 0-3 R 13 c ;
  • R 13c is selected from C ⁇ _ 6 alkyl, C 3 - 6 cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ - 5 alkyl, (CH 2 ) r OH, (CH 2 ) r SC ⁇ _ 5 alkyl, and (CH 2 ) r NR 13d Rl 3d ;
  • R 13d is selected from H, C ⁇ _g alkyl, and C 3 - 6 cycloalkyl;
  • R 15 at each occurrence, is selected from C ⁇ _ 8 alkyl, (CH 2 ) r C 3 _ 6 cycloalkyl, Cl, Br, I, F, N0 2 , CN, (CHR') r NR 15a R 15a ⁇ (CHR') r OH, (CHR' ) r 0 (CHR' ) r R 15d , (CHR') r SH, (CHR') r C(0)H, (CHR' ) r S (CHR' ) r R 15d , (CHR' ) r C (0) OH, (CHR' ) r C (0) (CHR' ) r R 15b , (CHR' ) r C (0) NR 15a R 15a ' , (CHR' ) r NR 15f C
  • R' at each occurrence, is selected from H, C ⁇ _ 6 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, (CH 2 ) r C 3 _ 6 cycloalkyl, and (CH 2 ) r phenyl substituted with R 15e ;
  • R 15a and R 15a ' are selected from H, C ⁇ -s alkyl, C 3 _ 8 alkenyl, C 3 _ 8 alkynyl, a (CH 2 ) r -C 3 - ⁇ o carbocyclic residue substituted with 0-5 R 15e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 R 15e ;
  • R 15a and R 15a ' join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 15 s, O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R 15b at each occurrence, is selected from C ⁇ _ 6 alkyl, C 3 - 8 alkenyl, C 3 _8 alkynyl, a (CH 2 ) r _ 3 _ 6 carbocyclic residue substituted with 0-3 R 15e , and (CH 2 ) r _ 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 15e ;
  • R 1 d is selected from C 3 _ 8 alkenyl, C 3 - 8 alkynyl, methyl, CF 3 , C 2 _ 6 alkyl substituted with 0-3
  • R 15e a (CH 2 ) r -C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R 15e , and a (CH 2 ) r 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 15e ;
  • R 15e is selected from C -Q alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) r C 3 _ 6 cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OCi_ 5 alkyl, OH, SH, (CH 2 ) r SC ⁇ - 5 alkyl, (CH 2 ) r NR 15f R 15f , and (CH 2 ) r phenyl;
  • R 15f is selected from H, Ci- ⁇ alkyl, C 3 - 6 cycloalkyl, and phenyl;
  • R l5g i s selected from H, Ci- 6 alkyl, C 3 - 6 cycloalkyl, (CH 2 ) r phenyl, C(0)R 15f , C(0)OR 15h , and S ⁇ 2R 15h ;
  • R 15h is selected from C ⁇ _ 5 alkyl, and C 3 - 6 cycloalkyl;
  • R 16 at each occurrence, is selected from C ⁇ _s alkyl, C 2 _ 8 alkenyl, C 2 _ ⁇ alkynyl, (CH 2 ) r C 3 - 6 cycloalkyl, Cl, Br, I, F, N0 2 , CN, (CHR') r NR 16a R 16a ', (CHR') r OH,
  • Rl6a an ci Ri6 a ' a t each occurrence are selected from H, Ci-g alkyl, C 3 .- 8 alkenyl, C 3 - 8 alkynyl, a (CH 2 ) r -C 3 _ ⁇ o carbocyclic residue substituted with 0-5 R 16e , and a
  • R 16b at each occurrence, is selected from C ⁇ -Q alkyl, C 3 _ 8 alkenyl, C 3 .- 8 alkynyl, a (CH 2 ) r C 3 _ 6 carbocyclic residue substituted with 0-3 R 16e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms
  • R 16d is selected from C 3 _ 8 alkenyl, C 3 - 8 alkynyl, methyl, CF 3 , C 2 _ 6 alkyl substituted with 0-3
  • R 16e a (CH 2 ) r -C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R 16e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 16e ;
  • R 16e is selected from C ⁇ _ 6 alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) r C 3 - 6 cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, OH, SH,
  • R 16f at each occurrence, is selected from H, C ⁇ _ 5 alkyl, and C3-6 cycloalkyl, and phenyl; v is selected from 1 and 2 ;
  • t is selected from 1 and 2;
  • w is selected from 0 and 1;
  • r is selected from 0, 1, 2, 3, 4, and 5;
  • q is selected from 1, 2, 3, 4, and 5;
  • p is selected from 0, 1, and 2.
  • the present invention provides novel compounds of formula (I) :
  • R 4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C ⁇ _ 8 alkyl, (CH 2 ) r C 3 - 6 cycloalkyl, and (CH 2 ) r -phenyl substituted with 0-3 R 4c ;
  • R c is selected from - ⁇ alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, C 3 - 6 cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OCi- 5 alkyl, (CH 2 ) r OH, (CH 2 ) r SCi_ 5 alkyl, (CH 2 ) r NR a R a ' , and (CH 2 ) r pheny1 ;
  • R 4 joins with R 7 , R 9 , or R 11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 R a ;
  • R 1 and R 2 are independently selected from H and C 1 - 4 alkyl
  • R 6 is selected from C ⁇ _ 4 alkyl, C 2 _s alkenyl, C 2 -8 alkynyl, (CH 2 ) r C3- 6 cycloalkyl, (CF 2 ) r CF 3 , CN, (CH 2 ) r OH, (CH 2 ) r OR sb , (CH 2 ) r C (O) R 6b , (CH 2 ) r C(0)NR 6a R 6a ', (CH 2 ) r NR 6d C(0)R 6a , and (CH 2 ) t phenyl substituted with 0-3 R 5c ;
  • R 6a and R ⁇ a ' are selected from H, C ⁇ - ⁇ alkyl, C 3 _ 6 cycloalkyl, and phenyl substituted with 0-3 R 6c ;
  • R 6b at each occurrence, is selected from C ⁇ _ 6 alkyl, C 3 _g cycloalkyl, and phenyl substituted with 0-3 R 6c ;
  • R 6c is selected from C ⁇ _ 6 alkyl, C 3 - 6 cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, (CH 2 ) r OH, (CH 2 ) r SC ⁇ _ 5 alkyl, and (CH 2 ) r NR 6d R 6d ;
  • R 6d at each occurrence, is selected from H, C - 6 alkyl, and C 3 - 6 cycloalkyl;
  • R 13 is selected from C ⁇ _ 4 alkyl, C 3 - 6 cycloalkyl, (CH )NR 13 Rl a' # (CH 2 )OH, (CH 2 )OR 13b , (CH 2 ) w C(0)R 13b , (CH 2 ) w C(0)NR 13a Rl3a', (CH 2 )NR 13 C (O) R 13a , (CH 2 ) w S(0) 2 NR 13a Rl3a' / (CH 2 )NR 13 S (O) 2 R 13b , and (CH 2 ) w -phenyl substituted with 0-3 R 13c ;
  • R 13 and R 13a ' are selected from H, C ⁇ _ 6 alkyl, C 3 .- 6 cycloalkyl, and phenyl substituted with 0-3 R 13c.
  • R 13b at each occurrence, is selected from C ⁇ _ 6 alkyl, C 3 - 6 cycloalkyl, and phenyl substituted with 0-3 R 13c ;
  • R 13c at each occurrence, is selected from Ci- 6 alkyl , C 3 _ 6 cycloalkyl , Cl , F, Br, I , CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ - 5 alkyl , (CH 2 ) r OH, and (CH 2 ) r NR 13d R 13d ;
  • R 13d at each occurrence, is selected from H, C ⁇ - ⁇ alkyl, and C 3 - 6 cycloalkyl;
  • v is selected from 1 and 2;
  • q is selected from 1, 2, and 3;
  • r is selected from 0, 1, 2, and 3.
  • R 3 is selected from a (CR 3 'H) r -carbocyclic residue substituted with 0-5 R 15 , wherein the carbocyclic residue is selected from phenyl, C 3 - 6 cycloalkyl, naphthyl, and adamantyl; and a (CR 3 'H) r -heterocyclic system substituted with 0-3 R 15 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,
  • R 5 is selected from (CR 5 'H) -phenyl substituted with 0-5 R 15 ; and a (CR 5 'H) t-heterocyclic system substituted with 0-3 R 16 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1, 2, 4-triazolyl, 1, 2 , 3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyraziny
  • the present invention provides novel compounds of formula (I-i) :
  • R 16 at each occurrence, is selected from C ⁇ _ 8 alkyl, (CH 2 ) r C 3 -g cycloalkyl, CF 3 , Cl, Br, I, F,
  • R l ⁇ a and R 16a ' are selected from H, C_g alkyl, C3_ cycloalkyl, and (CH 2 ) r Phenyl substituted with 0-3 R 16e ;
  • R 16b at each occurrence, is selected from H, C ⁇ _g alkyl, 3 - cycloalkyl, and (CH 2 ) r phenyl substituted with 0-3 R 16e ;
  • R 16d at each occurrence, is selected from C ⁇ _g alkyl and phenyl;
  • R l ⁇ e at each occurrence, is selected from C ⁇ _g alkyl, Cl,
  • R 16f at each occurrence, is selected from H, and C 1 - 5 alkyl .
  • the present invention provides novel compounds of formula (I-i) :
  • R 5 is CH 2 phenyl substituted with 0-3 R 16 ;
  • r is selected from 0, 1, and 2.
  • the present invention provides novel compounds of formula (I-i) :
  • K is CHR 5 ;
  • L is selected from CH 2 and CHR 5 ;
  • R 3 is a C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R 15 , wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR 3 'H) r -heterocyclic system substituted with 0-3 R 15 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl,
  • R 15 at each occurrence, is selected from C 1 - 8 alkyl, (CH 2 ) r C 3 _g cycloalkyl, CF 3 , Cl, Br, I, F,
  • R 15a and R 15a ' are selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, and (CH 2 ) r phenyl substituted with 0-3 R 15e ;
  • R 15a and R 15a ' along with the N to which they are attached, join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 15 ⁇ , O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R 15b at each occurrence, is selected from H, C ⁇ _g alkyl, C 3 _ cycloalkyl, and (CH 2 ) r Phenyl substituted with 0-3 R 15e.
  • R 15d is selected from C ⁇ _g alkyl and phenyl ;
  • R 15e is selected from C ⁇ _ 6 alkyl, Cl,
  • R 15f is selected from H, and C 1 - 5 alkyl .
  • the present invention provides novel compounds of formula (I) : M is CH 2 ;
  • J is CH 2 ;
  • K is CHR 5 ;
  • L is CH 2 ;
  • R 1 is H
  • R 2 is H
  • R 3 is a C 3 - 10 carbocyclic residue substituted with 0-3 R 15 , wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR 3 'H) r -heterocyclic system substituted with 0-3 R 15 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,
  • R 5 is selected from a CH -C 3.10 carbocyclic residue substituted with 1-5 R 16 and a heterocyclic system substituted with 0-3 R 15 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1, 2 , -triazolyl, 1, 2, 3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and
  • R 11 and R 12 join to form cyclopropyl.
  • M is absent or selected from CH , CHR 5 , CHR 13 , CR 13 R 13 , and CR 5 R 13 ;
  • Q is selected from CH 2 , CHR 5 , CHR 13 , CR 13 R 13 , and CR 5 R 13 ;
  • J and K are independently selected from CH 2 , CHR 5 , CHR 6 , CR 6 R 6 and CR 5 R 6 ;
  • L is selected from CHR 5 and CR 5 R 6 ;
  • J is selected from CH 2 , CHR 5 , CHR 13 , and CR 5 R 13 ;
  • Z is selected from 0 and S;
  • E is -(CR 7 R 8 )-(CR 9 R 1 0) v -(CR 11 R 12 )-;
  • R 1 and R 2 are independently selected from H, C ⁇ _s alkyl, C 3 _s alkenyl, C 3 .- 8 alkynyl, (CH 2 ) r C 3 _g cycloalkyl, and a (CH 2 ) r -C 3 _ ⁇ o carbocyclic residue substituted with 0-5 R a ;
  • R b at each occurrence, is selected from H, C - 6 alkyl, C 3 -g cycloalkyl, and phenyl;
  • R c at each occurrence, is selected from Ci-g alkyl, C 3 - cycloalkyl, and phenyl;
  • R 2 and R 3 join to form a 5, 6, or 7-membered ring substituted with 0-3 R a ;
  • R 3 is selected from a (CR 3 'R 3 ") r _c 3 _ ⁇ o carbocyclic residue substituted with 1 R 15 ' and 0-4 R 15 and a (CR 3 'R 3 ") r -5- 10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 1 R 15b and 0-2 R 15 ;
  • R 3 ' and R 3 " are selected from H, C ⁇ _g alkyl, (CH 2 ) r 3 - 6 cycloalkyl, and phenyl;
  • R 4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C ⁇ _ 8 alkyl, C 3 _ 8 alkenyl, C 3 - 8 alkynyl, (CH 2 ) r C 3 - 6 cycloalkyl, (CH 2 ) g C (0)R 4b , (CH 2 ) g C (0)NR 4a R 4a ' , (CH 2 ) q C(0)OR 4b , and a (CH ) r -C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R c ;
  • R 4a and R 4a ' are selected from H, C ⁇ _ alkyl, (CH ) r C 3 -g cycloalkyl, and phenyl;
  • R b at each occurrence, is selected from C ⁇ _g alkyl, C 3 _s alkenyl, (CH 2 ) r C 3 -g cycloalkyl, C 3 - 8 alkynyl, and phenyl;
  • R c is selected from C ⁇ _g alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, C 3 -g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ! _ 5 alkyl, (CH 2 ) r OH, (CH 2 ) r SC ⁇ - 5 alkyl, (CH 2 ) r NR a R 4a ' , and (CH 2 ) r pheny1 ;
  • R 4 joins with R 7 , R 9 , or R 11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 R a ;
  • R 5 is selected from a (CR 5 'R 5 ") t _ 3 _ ⁇ o carbocyclic residue substituted with 0-5 R 16 and a (CR 5 'R 5 ") t -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 16 ;
  • R 5 ' and R 5 " are selected from H, C ⁇ _g alkyl, (CH 2 ) r C 3 -g cycloalkyl, and phenyl;
  • R 6 is selected from C ⁇ _g alkyl, C 2 _s alkenyl, C 2 _ 8 alkynyl, (CH 2 ) r C 3 _g cycloalkyl, (CF 2 ) r CF 3 , CN, (CH 2 ) r NR 6a R 6a ', (CH 2 ) r OH, (CH 2 ) r 0R 6b , (CH 2 ) r SH, (CH 2 ) r SR 6b , (CH 2 ) r C(0)OH, (CH 2 ) r C (0) R 6b , (CH 2 ) r C(0)NR 6a R 6a ' ; (CH 2 ) r NR 6d C(0)R 6a , (CH 2 ) r C (0) OR 6b , (CH 2 ) r OC(0)R 6b , (CH 2 ) r S(0) p R 6b , (CH 2 ) r S(0) p R 6b
  • R 6a and R 6a ' are selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, and phenyl substituted with 0-3 R 6c.
  • R 6b at each occurrence, is selected from C ⁇ _g alkyl, C 3 _g cycloalkyl, and phenyl substituted with 0-3 R 6c ;
  • R 6c is selected from C ⁇ _g alkyl, C 3 -g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, (CH 2 ) r OH, (CH 2 ) r SC ⁇ _ 5 alkyl, and (CH 2 ) r NR 6d R 6d ;
  • R 6d at each occurrence, is selected from H, C ⁇ _g alkyl, and C 3 _ cycloalkyl;
  • R 7 is selected from H, C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) q 0H, (CH 2 ) q SH, (CH 2 ) q OR 7d , (CH 2 ) q SR 7d , (CH 2 ) q NR 7a R 7a ', (CH 2 ) r C(0)OH, (CH 2 ) r C (0) R 7b , (CH 2 ) r C (0) NR 7a R 7a ' , (CH 2 ) q NR 7a C (0) R 7b ,
  • R 7b is selected from C ⁇ _g alkyl, C 3 _ 8 alkenyl, C 3 _ 8 alkynyl, a (CH 2 ) r -C 3 _g carbocyclic residue substituted with 0-2 R 7e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 7e ;
  • R 7c is selected from C _g alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) r C 3 -g cycloalkyl, Cl, Br, I, F, (CF 2 ) r CF 3 , N0 2 , CN, (CH 2 ) r NR 7 f R 7 f , (CH 2 ) r OH, (CH 2 ) r OCi_ alkyl, (CH 2 ) r SC ⁇ _ alkyl, (CH 2 ) r C (O) OH, (CH 2 ) r C(0)R 7b , (CH 2 ) r C(0)NR 7f R 7f , (CH 2 ) r NR 7f C (0)R 7a , (CH 2 ) r C(0)0Ci- 4 alkyl, (CH 2 ) r 0C (O) R 7b , (CH 2 ) r C(
  • R 7d is selected from C ⁇ _g alkyl, C 3 _s alkenyl, C 3 _ 8 alkynyl, and a C 3 - 10 carbocyclic residue substituted with 0-3 R 7c ;
  • R 7e at each occurrence, is selected from C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 _s alkynyl, C 3 _ cycloalkyl, Cl, F, Br, I,
  • R 7f at each occurrence, is selected from H, Ci- alkyl, and 3 -g cycloalkyl;
  • R 8 is selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, and (CH 2 ) r phenyl substituted with 0-3 R 8a ;
  • R 8a is selected from C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, C 3 -g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, OH, SH, (CH 2 ) r SC ⁇ _ 5 alkyl, (CH 2 ) r NR 7f R 7f , and (CH 2 ) r phenyl;
  • R 8b is selected from H, C -g alkyl, C 3 -g cycloalkyl, OH, CN, and (CH 2 ) r -phenyl ;
  • R 9 is selected from H, C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 _s alkynyl, F, Cl, Br, I, N0 2 , CN, (CH 2 ) q OR 9d , (CH 2 ) q SR 9d , (CH 2 ) r NR 9a R 9a ', (CH 2 ) r C(0)OH, (CH 2 ) r C (0) R 9b , (CH 2 ) r NR 9a C(0)R 9a , (CH 2 ) r NR 9a C(0)H, (CH 2 ) r NR 9a C (0)NHR 9a , (CH 2 ) r C(0)OR 9a , (CH 2 ) r OC(0)R 9b , (CH 2 ) r S (0) p R 9b , (CH 2 ) r S(0) 2 NR 9a R 9a ', (CH 2 ) r NR 9a S(0) 2
  • R 9a and R 9a ' are selected from H, C ⁇ _g alkyl, C 3 - 8 alkenyl, C 3 - 8 alkynyl, a (CH 2 ) r -C3_ 0 carbocyclic residue substituted with 0-5 R 9e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 9e ;
  • R 9a and R 9 ' along with the N to which they are attached, join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 9 ⁇ , 0, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R 9b is selected from C ⁇ _g alkyl, C 3 _s alkenyl, C 3 - 8 alkynyl, a (CH 2 ) r -C 3 _g carbocyclic residue substituted with 0-2 R 9e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 9e ;
  • R 9c is selected from C ⁇ _ alkyl, C _ 8 alkenyl, C 2 _ 8 alkynyl, (CH 2 ) r C 3 -g cycloalkyl, Cl, Br, I,
  • R 9d is selected from C ⁇ _ 6 alkyl, C 3 -g alkenyl, C 3 -g alkynyl, a C 3 - 10 carbocyclic residue substituted with 0-3 R 9c , and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R 9c ;
  • R 9e is selected from C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, (CH ) r C 3 _g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC 1 _ 5 alkyl, OH, SH, (CH 2 ) r SC ⁇ _ 5 alkyl, (CH 2 ) r NR 9f R 9f , and (CH 2 ) r phenyl ;
  • R 9f at each occurrence, is selected from H, Ci-g alkyl, and C 3 -g cycloalkyl;
  • R 9 3 is selected from H, C ⁇ _g alkyl, C 3 - cycloalkyl, (CH 2 ) r phenyl, C(0)R 9f , C(0)OR 9h , and S ⁇ 2R 9h ;
  • R 9h at each occurrence, is selected from C ⁇ _ 5 alkyl, and C 3 - 6 cycloalkyl;
  • R 10 is selected from H, C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, F, Cl, Br, I, N0 2 , CN, (CH 2 ) g OR 10d , (CH 2 ) q SR 10d , (CH 2 ) r NR 10a R 10a ', (CH 2 ) r C (O) OH,
  • R 10a and R 10a ' are selected from H, C ⁇ _g alkyl, C 3 _ 8 alkenyl, C 3 - 8 alkynyl, a (CH 2 ) r -C 3 _ ⁇ o carbocyclic residue substituted with 0-5 R 10e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 10e ;
  • R 10a and R 10a ' along with the N to which they are attached, join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 10 ⁇ , 0, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R 10b is selected from C ⁇ _g alkyl, C 3 -. 8 alkenyl, C 3 _ 8 alkynyl, a (CH 2 ) r -C 3 _g carbocyclic residue substituted with 0-2 R 10e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 10e ;
  • R 10c is selected from C ⁇ _g alkyl, C 2 _s alkenyl, C 2 _s alkynyl, (CH 2 ) r C 3 -g cycloalkyl, Cl, Br, I, F, (CF 2 ) r CF 3 , N0 2 , CN, (CH 2 ) r NR 10f R 10f , (CH 2 ) r 0H, (CH 2 ) r OCi_ 4 alkyl, (CH 2 ) r SC ⁇ - alkyl, (CH 2 ) r C (0)0H, (CH 2 ) r C(O)R 10b , (CH 2 ) r C(O)NR 10f R 10f , (CH 2 ) r NR 10f C (0) R 10a , (CH 2 ) r C(0)0Ci_ alkyl, (CH 2 ) r 0C (0) R 10b ,
  • R 10d is selected from C ⁇ _g alkyl, C 3 _g alkenyl, C 3 _g alkynyl, a C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R 10c , and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R 10c ;
  • R 10e is selected from C ⁇ _g alkyl, C 2 _s alkenyl, C 2 _s alkynyl, (CH 2 ) r C 3 _g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OCi_ 5 alkyl, OH, SH,
  • R 10f is selected from H, Ci-g alkyl, and C 3 - cycloalkyl; R lOg i s selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, (CH 2 ) r phenyl, C(O)R 10f , C(O)OR 10h , and SO 2 R 10h ;
  • R 10h at each occurrence, is selected from C ⁇ _ 5 alkyl, and 3 -g cycloalkyl;
  • R 9 on adjacent carbon atoms form a bond, thereby forming a double bond, or R 9 and R 10 on adjacent carbon atoms each form a bond thereby forming a triple bond;
  • R 11 is selected from H, C ⁇ _g alkyl, C _ 8 alkenyl, C 2 _s alkynyl, (CH 2 ) q 0H, (CH 2 ) q SH, (CH 2 ) q 0R lld , (CH 2 ) q SR lld , (CH 2 ) q NR la R lla ', (CH 2 ) r C(0)0H, (CH 2 ) r C (0) R llb , (CH 2 ) r C (O) NR lla R lla ' , (CH 2 ) q NR lla C (O) R ll , (CH 2 ) q NR lla ', (CH 2 ) OC(0)NR lla R lla ', (CH 2 ) q NR ll C (O) OR llb ,
  • R lla and R lla ' are selected from H, Ci-g alkyl, C 3 _ 8 alkenyl, C 3 _ 8 alkynyl, a (CH ) r -C 3 _ ⁇ o carbocyclic residue substituted with 0-5 R lle , and a (CH 2 ) r _ 5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R lle ;
  • R a and R lla ' join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 11 ⁇ , 0, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R llb at each occurrence, is selected from C ⁇ _g alkyl, C 3 _s alkenyl, C 3 .- 8 alkynyl, a (CH 2 ) r -C 3 _g carbocyclic residue substituted with 0-2 R lle , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R lle ;
  • R llc at each occurrence, is selected from C ⁇ _g alkyl, C 2 _ 8 alkenyl, C _ 8 alkynyl, (CH ) r C 3 _g cycloalkyl, Cl, Br, I, F, (CF 2 ) r CF 3 , N0 2 , CN, (CH 2 ) r NR llf R llf , (CH 2 ) r OH,
  • R lld is selected from methyl, CF 3 , C _g alkyl substituted with 0-3 R lle , C 3 _g alkenyl, C 3 -g alkynyl, and a C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R llc ;
  • R lle at each occurrence, is selected from C ⁇ _g alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, C 3 _g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r 0Ci_ 5 alkyl, OH, SH, (CH 2 ) r SCi- 5 alkyl, (CH 2 ) r NR llf R llf , and (CH 2 ) r phenyl ;
  • R llf at each occurrence, is selected from H, C ⁇ _g alkyl, and C 3 _g cycloalkyl;
  • R iig is selected from H, C ⁇ _g alkyl, C 3 _ cycloalkyl, (CH 2 ) r phenyl, C(0)R llf , C(0)OR llh , and S0 2 R llh ;
  • R llh at each occurrence, is selected from Ci-g alkyl, and C 3 _ cycloalkyl;
  • R 12 is selected from H, C ⁇ _g alkyl, (CH 2 ) q OH, (CH 2 ) r C 3 _g cycloalkyl, and (CH 2 ) t phenyl substituted with 0-3 R 12a ;
  • R 12a is selected from Ci-g alkyl, C _ 8 alkenyl, C 2 _ 8 alkynyl, C 3 - cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OCi_ 5 alkyl, OH, SH, (CH 2 ) r SCi- 5 alkyl, (CH 2 ) r NR 9 f R 9 f , and (CH 2 ) r pheny1 ;
  • R 11 and R 12 join to form a cyclic structure wherein the cyclic structure is selected from C 3 _ o carbocycle, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and
  • R 9 and R 10 , or R 11 and R 12 join to form the cyclic structure, or R 9 on adjacent carbon atoms form a bond, thereby forming a double bond, or R 9 and R 10 on adjacent carbon atoms each form a bond thereby forming a triple bond when v is equal to 2 ;
  • R 13 at each occurrence, is selected from C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, C 3 -g cycloalkyl, (CF 2 ) W CF 3 , (CH 2 ) q NR 13a R 13a ', (CH 2 ) q OH, (CH 2 ) q OR 13b , (CH 2 ) q SH, (CH 2 ) q SR 13b , (CH 2 ) w C(0)OH, (CH 2 ) W C (0) R 13b , (CH 2 ) w C(0)NR 13a R 13a ⁇ (CH 2
  • R 13a and R 13a ' are selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, and phenyl substituted with 0-3 R 13c.
  • R 13b at each occurrence, is selected from C ⁇ _g alkyl, C 3 _g cycloalkyl, and phenyl substituted with 0-3 R 13c ;
  • R 13c is selected from C ⁇ _g alkyl, C 3 _ cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, (CH 2 ) r OH, (CH 2 ) r SC ⁇ _ 5 alkyl, and (CH 2 ) r NR 13d R 13d ;
  • R 13d at each occurrence, is selected from H, C ⁇ _g alkyl, and C 3 _g cycloalkyl;
  • R 15 ' is selected from C 2 - 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) r C 3 _g cycloalkyl, (CHR') r SH, (CHR') 3 _ 5 C(0)H, (CHR') r S(CHR') r R 15d , (CHR' ) q C (O) OH, (CHR') q C(0) (CHR') q R 15b , (CHR' ) r C (0) NR 15a R 15a ' , (CHR') r NR 15f C(0) (CHR') r R 15b , (CHR' ) r OC (0)NR 15a R 15 ' , (CHR' ) r NR 15f C (0)0 (CHR' ) r R 15b , (CHR' ) r C (O) O (CHR' ) r R 15d , (
  • R' at each occurrence, is selected from H, C ⁇ _ alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, (CH 2 ) r C 3 _g cycloalkyl, and (CH 2 ) r phenyl substituted with R 15e ;
  • R 15a and R 15a ' are selected from H, Ci-g alkyl, C 3 -8 alkenyl, C 3 _ 8 alkynyl, a (CH 2 )r-C3- ⁇ o carbocyclic residue substituted with 0-5 R 15e , and a
  • (CH 2 ) r ⁇ 5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 R 15e ; alternatively, R 15a and R 15a ' , along with the N to which they are attached, join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 15 9, 0, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R 15b is selected from C ⁇ _g alkyl, C 3 _ 8 alkenyl, C 3 - 8 alkynyl, a (CH 2 ) r ⁇ 3 -g carbocyclic residue substituted with 0-3 R 15e , and (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 15e ;
  • R 15d is selected from C 3 _ 8 alkenyl, C 3 _s alkynyl, methyl, CF 3 , C 2 -g alkyl substituted with 0-3 R 15e , a (CH 2 ) r -C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R 15e , and a (CH 2 ) r 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 15e ;
  • R 15e is selected from C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) r C 3 -g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OCi_ 5 alkyl, OH, SH, (CH 2 ) r SCi_ 5 alkyl, (CH 2 ) r NR 15f R 15f , and (CH 2 ) r phenyl ;
  • R 15f is selected from H, Ci-g alkyl, 3 - cycloalkyl, and phenyl;
  • R 15 3 is selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, (CH 2 ) r phenyl, C(0)R 15f , C(0)OR 15i , and S ⁇ 2R 15i ;
  • R 15h is selected from (CH 2 ) r C 3 _ 6 cycloalkyl, (CHR' ) q NR 15a R 15a ' , (CHR') q SH, (CHR' ) r C (O)H,
  • R 15i is selected from Ci-g alkyl, and C 3 _g cycloalkyl;
  • R 16 is selected from C ⁇ _s alkyl, C 2 _s alkenyl, C 2 _ 8 alkynyl, (CH 2 ) r C 3 -g cycloalkyl, Cl, Br, I, F, N0 2 , CN, (CHR') r NR 16a R 16a ', (CHR') r OH, (CHR') r O(CHR') r R 16d , (CHR') r SH, (CHR' ) r C (O) H, (CHR' ) r S (CHR' ) r R 16d , (CHR' ) r C (O) OH, (CHR') r C(0) (CHR') r R 15b , (CHR' ) r C (0)NR 16a R 16a ' , (CHR' ) r NR 16f C (O) (CHR' ) r R 16b , (
  • R l6a a ⁇ d i 6a' f a ⁇ ach occurrence are selected from H, C 1 - g alkyl, C 3 _ 8 alkenyl, C 3 -s alkynyl, a (CH ) r -C 3 _ ⁇ o carbocyclic residue substituted with 0-5 R 16e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 R 16e ;
  • R 16b is selected from C ⁇ _g alkyl, C 3 - 8 alkenyl, C 3 - 8 alkynyl, a (CH 2 ) r C 3 _g carbocyclic residue substituted with 0-3 R 16e , and a (CH ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 16e ;
  • R 16d is selected from C 3 - 8 alkenyl, C 3 _ 8 alkynyl, methyl, CF 3 , C 2 _g alkyl substituted with 0-3
  • R 16e a (CH 2 ) r ⁇ C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R 16e , and a (CH ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 16e ;
  • R 16e is selected from C ⁇ _g alkyl, C 2 _ 8 alkenyl, C 2 -s alkynyl, (CH 2 ) r 3 -g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OCi- 5 alkyl, OH, SH,
  • R 16f at each occurrence, is selected from H, C 1 - 5 alkyl, and C 3 _g cycloalkyl, and phenyl;
  • v is selected from 0, 1, and 2;
  • t is selected from 1 and 2;
  • w is selected from 0 and 1;
  • r is selected from 0, 1, 2, 3, 4, and 5;
  • q is selected from 1, 2, 3, 4, and 5;
  • R 4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C ⁇ _ 8 alkyl, (CH ) r C 3 _g cycloalkyl, and (CH 2 ) r -phenyl substituted with 0-3 R 4c ;
  • R c is selected from Ci-g alkyl, C _s alkenyl, C _s alkynyl, C 3 - cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC!- 5 alkyl, (CH 2 ) r OH, (CH 2 ) r SC ⁇ - 5 alkyl, (CH 2 ) r NR a R 4a ' , and (CH 2 ) r -phenyl ;
  • R 4 joins with R 7 , R 9 , or R 11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 R a ;
  • R 1 and R 2 are independently selected from H and C 1 - 4 alkyl
  • R 6 at each occurrence, is selected from C ⁇ _ 4 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, (CH 2 ) r C 3 - 6 cycloalkyl, (CF 2 ) r CF 3 , CN, (CH 2 ) r OH, (CH 2 ) r OR 6b , (CH 2 ) r C (0) R 6b ,
  • R 6a and R 6a ' are selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, and phenyl substituted with 0-3
  • R 6b at each occurrence, is selected from C ⁇ _g alkyl, C 3 _g cycloalkyl, and phenyl substituted with 0-3 R 6c ;
  • R 6c at each occurrence, is selected from C ⁇ _g alkyl, C 3 _ cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, (CH 2 ) r 0H, (CH 2 ) r SC ⁇ _ 5 alkyl, and (CH 2 ) r NR 6d R 6d ;
  • R 6d at each occurrence, is selected from H, C ⁇ _g alkyl, and C 3 -g cycloalkyl;
  • R 13 at each occurrence, is selected from C 1 - 4 alkyl, C 3 - cycloalkyl, (CH 2 )NR 13a R 13a ' , (CH 2 )OH, (CH 2 )OR 13b , (CH 2 ) w C(0)R 13b , (CH 2 ) w C(0)NR 13a R 1 3a' / (CH 2 )NR 13d C (0) R 13 a,
  • R 13a and R 13a ' are selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, and phenyl substituted with 0-3
  • R 13b at each occurrence, is selected from C ⁇ _g alkyl, C 3 _ cycloalkyl, and phenyl substituted with 0-3 R 13c ;
  • R 13c at each occurrence, is selected from C ⁇ _g alkyl, C 3 - cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r 0C ⁇ _ 5 alkyl, (CH 2 ) r OH, and (CH 2 ) r NR 13d R 13d ;
  • R 13d at each occurrence, is selected from H, C ⁇ _g alkyl, and C 3 _g cycloalkyl;
  • v is selected from 0, 1, and 2;
  • q is selected from 1, 2, and 3;
  • r is selected from 0, 1, 2, and 3.
  • R 3 is selected from a (CR 3 'H) r -carbocyclic residue substituted with 1 R 15 ' and 0-4 R 15 , wherein the carbocyclic residue is selected from phenyl, C 3 _ cycloalkyl, naphthyl, and adamantyl; and a (CR 3 'H) r - heterocyclic system substituted with 1 R 15h and 0-2 R 15 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, iso
  • R 5 is selected from (CR 5 'H) t-phenyl substituted with 0-5
  • R 16 and a (CR 5 'H) t -heterocyclic system substituted with 0-3 R 16 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1, 2 , 4-triazolyl, 1, 2, 3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl.
  • the heterocyclic system is selected from pyridin
  • the present invention provides novel compounds of formula (I-i) :
  • R 16 at each occurrence, is selected from C ⁇ _ 8 alkyl, (CH 2 ) r C 3 -g cycloalkyl, CF 3 , Cl, Br, I, F,
  • R 16a and R 16a ' are selected from H, C _g alkyl, C 3 _g cycloalkyl, and (CH 2 ) r phenyl substituted with 0-3 R 16e ;
  • R 16b at each occurrence, is selected from H, C ⁇ _g alkyl,
  • R 16d at each occurrence, is selected from C ⁇ _g alkyl and phenyl;
  • R 16e at each occurrence, is selected from C ⁇ _g alkyl, Cl,
  • R 16f at each occurrence, is selected from H, and C 1 - 5 alkyl.
  • the present invention provides novel compounds of formula (I-ii) :
  • R 16 at each occurrence, is selected from Ci-s alkyl
  • R 16a and R 16a ' are selected from H, C ⁇ _g alkyl, C 3 _ cycloalkyl, and (CH 2 ) r phenyl substituted with 0-3 R 16e ;
  • R 16b at each occurrence, is selected from H, C ⁇ _g alkyl,
  • R 16d at each occurrence, is selected from C ⁇ _g alkyl and phenyl ;
  • R 16e at each occurrence, is selected from C ⁇ _ alkyl, Cl,
  • R 16f at each occurrence, is selected from H, and C 1 - 5 alkyl .
  • the present invention provides novel compounds of formula (I-i) :
  • R 5 is CH 2 phenyl substituted with 0-3 R 16 ;
  • E is selected from -CH 2 - (CR ⁇ R 12 ) , -CH -CH 2 - (CR ⁇ R 12 ) , -CH 2 - CH•CH- (CR 1:L R 12 ) , and -CH 2 -CH•CH- (CR 1:L R 12 ) ;
  • R 11 and R 12 join to form a C 3 .- 10 cycloalkyl selected from cyclopropyl, cyclopentyl and cyclohexyl; r is selected from 0, 1, and 2.
  • the present invention provides novel compounds of formula (I-ii) :
  • E is selected from -CH 2 - (CR 1:L R 12 ) , -CH -CH 2 - (CR ⁇ R 12 ) , -CH 2 - CH.CH- (CR 1:L R 12 ) , and -CH -CH-CH- (CR ⁇ R 12 ) ;
  • R 5 is CH 2 phenyl substituted with 0-3 R 16 ;
  • R 11 and R 12 join to form a C 3 -. 10 carbocycle selected from cyclopropyl, cyclopentyl and cyclohexyl;
  • r is selected from 0, 1, and 2.
  • the present invention provides novel compounds of formula (I-i) :
  • J is selected from CH 2 and CHR 5 ;
  • K is selected from CH and CHR 5 ;
  • L is CHR 5 ;
  • R 3 is a C 3 _ ⁇ o carbocyclic residue substituted with 1 R 15 ' and
  • the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR 3 'H) r -heterocyclic system substituted with 1 R 15h and 0-2 R 15 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, morpholinyl, piperidinyl, pyrrazolyl, 1, 2, 4-triazolyl, 1,
  • R 15 at each occurrence, is selected from C ⁇ _ 8 alkyl, (CH 2 ) r C 3 -g cycloalkyl, CF 3 , Cl, Br, I, F,
  • R 15a and R 15a ' are selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, and (CH 2 ) r phenyl substituted with 0-3 R 15e ;
  • R 15a and R 15a ' along with the N to which they are attached, join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 15 ⁇ , O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R 15b at each occurrence, is selected from H, C ⁇ _g alkyl, 3 -g cycloalkyl, and (CH 2 ) r phenyl substituted with 0-3 R 15e.
  • R 15d is selected from C ⁇ _g alkyl and phenyl ;
  • R 15e at each occurrence, is selected from C ⁇ _g alkyl, Cl,
  • R 15f at each occurrence, is selected from H, and C 3. - 5 alkyl .
  • the present invention provides novel compounds of formula (I-ii) :
  • K is selected from CH 2 and CHR 5 ;
  • L is CHR 5 ;
  • R 3 is a C 3 _io carbocyclic residue substituted with 1 R 15 ' and
  • the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR 3 'H) r -heterocyclic system substituted with 1 R 15h and 0-2 R 15 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, morpholinyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1, 2, 4-triazolyl, 1,
  • R 15 is selected from C ⁇ _ 8 alkyl, (CH 2 ) r C 3 -g cycloalkyl, CF 3 , Cl, Br, I, F, (CH 2 ) r NR 15a R 15a ', N0 2 , CN, OH, (CH 2 ) r OR 15d , (CH 2 ) r C(0)R 15b , (CH 2 ) r C(0)NR 15a R 15a ⁇ (CH 2 ) r NR 15f C (0) R 15 , (CH 2 ) r 0C(0)NR 15a R 15a ', (CH 2 ) r NR 15f C (O) 0R 15b ,
  • R 15a and R 15a ' along with the N to which they are attached, join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 15 ⁇ , O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R 15b at each occurrence, is selected from H, C ⁇ _ alkyl, c 3 -g cycloalkyl, and (CH ) r phenyl substituted with 0-3 R 15e.
  • R 15d is selected from C ⁇ _ alkyl and phenyl ;
  • R 15e is selected from C ⁇ _g alkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , OH, and (CH 2 ) r OC ⁇ _ 5 alkyl; and
  • R 15f is selected from H, and C 1 - 5 alkyl
  • the present invention provides novel compounds of formula (I) :
  • M is absent or selected from CH 2 ;
  • J is CH 2 ;
  • K is CH 2 ;
  • L is CHR 5 ; Z is 0;
  • R 1 is H
  • R 2 is H
  • R 3 is a C 3 _ ⁇ o carbocyclic residue substituted with 1 R 15 ' and
  • the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR 3 'H) r -heterocyclic system substituted with 1 R 15h and 0-2 R 15 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, morpholinyl, piperidinyl, pyrrazolyl, 1, 2 , 4-triazolyl
  • R 5 is selected from a CH 2 -C 3 _ 10 carbocyclic residue substituted with 1-5 R 16 and a heterocyclic system substituted with 0-3 R 15 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1, 2, 4-triazolyl, 1, 2, 3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl.
  • the present invention provides novel compounds of formula (I) : E is -(CH 2 )-(CR 9 R 10 ) V -(CR R 12 )-;
  • R 11 and R 12 join together to form a C 3 - 1 0 carbocycle, a 5-6- membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from O, S, and NR 11 ⁇ and optionally fused with a benzene ring or a 6-membered aromatic heterocycle.
  • the present invention provides novel compounds of formula (I) :
  • R 11 and R 12 join together to form a C 3 - 1 0 carbocycle, the carbocycle being selected from cyclopropyl, cyclobutyl, cyclopentyl, cylcohexyl, benzocyclopentyl, and benzocyclohexyl or a heterocycle, the heterocycle being selected from pyrrolidine, tetrahydrofuran, piperidine and tetrahydropyran.
  • the present invention provides novel compounds of formula (I-i) :
  • R 16 at each occurrence, is selected from C ⁇ _8 alkyl, (CH 2 ) r C 3 - 6 cycloalkyl, CF , Cl, Br, I, F,
  • R 16a and R 16a ' are selected from H, C _g alkyl, C 3 _ cycloalkyl, and (CH 2 ) r phenyl substituted with 0-3 R 16e ;
  • R 16b at each occurrence, is selected from H, Ci-g alkyl,
  • R 16d at each occurrence, is selected from C ⁇ _g alkyl and phenyl;
  • R 16e at each , occurrence, is selected from C _g alkyl, Cl,
  • R 16f at each occurrence, is selected from H, and C - 5 alkyl .
  • the present invention provides novel compounds of formula (I) :
  • R 5 is CH 2 phenyl substituted with 0-3 R 16 ;
  • r is selected from 0, 1, and 2.
  • the present invention provides novel compounds of formula (I) :
  • J is selected from CH 2 and CHR 5 ;
  • K is selected from CH 2 and CHR 5 ;
  • L is CHR 5 ;
  • R 3 is a C 3 _ ⁇ o carbocyclic residue substituted with 1 R 15 ' and 0-2 R 15 , wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR 3 'H) r -heterocyclic system substituted with 1 R 15h and 0-2 R 15 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, morph
  • R 15 at each occurrence, is selected from C ⁇ _ 8 alkyl, (CH 2 ) r C 3 _g cycloalkyl, CF 3 , Cl, Br, I, F,
  • R 15e and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 R 15e ;
  • R 15a and R 15a ' are selected from H, Ci-g alkyl, C 3 _g cycloalkyl, and (CH 2 ) r phenyl substituted with 0-3 R 15e ;
  • R 15 and R 15a ' join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 15 &, 0, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R 15b at each occurrence, is selected from H, C ⁇ _g alkyl,
  • R 15d is selected from C ⁇ _g alkyl and phenyl
  • R 15e at each occurrence, is selected from C ⁇ -g alkyl, Cl,
  • R 15f at each occurrence, is selected from H, and C 3. - 5 alkyl .
  • the present invention provides novel compounds of formula (I-ii) :
  • R 16 at each occurrence, is selected from C ⁇ _ 8 alkyl, (CH 2 ) r C 3 -g cycloalkyl, CF 3 , Cl, Br, I, F, (CH 2 ) r NR 16a R 16a ', N0 2 , CN, OH, (CH 2 ) r OR 16d ,
  • R 16a and R 16a ' are selected from H, C ⁇ _g alkyl, C 3 _ 6 cycloalkyl, and (CH 2 ) r phenyl substituted with 0-3 R 16e ;
  • R 16b at each occurrence, is selected from H, C ⁇ _g alkyl,
  • R 16d at each occurrence, is selected from C ⁇ _g alkyl and phenyl; R 16e , at each occurrence, is selected from C ⁇ _g alkyl, Cl,
  • R 16f at each occurrence, is selected from H, and C 1 - 5 alkyl .
  • R 5 is CHphenyl substituted with 0-3 R 16 ;
  • r is selected from 0, 1, and 2.
  • the present invention provides novel compounds of formula (I-ii) :
  • K is selected from CH and CHR 5 ;
  • L is CHR 5 ;
  • R 3 is a C 3 _io carbocyclic residue substituted with 1 R 15 ' and 0-2 R 15 , wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR 3 'H) r -heterocyclic system substituted with 1 R 15h and 0-2 R 15 , wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, morph
  • R 15a and R 15a ' are selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, and (CH ) r phenyl substituted with 0-3 R 15e ;
  • R 15a and R 15 ' along with the N to which they are attached, join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 15 ⁇ , 0, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R 15b at each occurrence, is selected from H, C ⁇ _ alkyl,
  • R 15d is selected from C ⁇ _g alkyl and phenyl ;
  • R 15e at each occurrence, is selected from C ⁇ _g alkyl, Cl,
  • R 15f at each occurrence, is selected from H, and C 1 - 5 alkyl.
  • R 15f at each occurrence, is selected from H, and C 1 - 5 alkyl.
  • the present invention provides novel compounds of formula (I) , wherein the compounds are selected from:
  • the present invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the present invention.
  • the present invention provides a method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention.
  • the present invention provides a method for treating inflammatory disorders comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention.
  • the present invention provides a method for treating or preventing disorders selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, bullous pemphigoid, helminthic parasitic infections, allergic colitis, eczema, conjunctivitis, transplantation, familial eosinophilia, eosinophilic cellulitis, eosinophilic pneumonias, eosinophilic fasciitis, eosinophilic gastroenteritis, drug induced eosinophilia, HIN infection, cystic fibrosis, Churg-Strauss syndrome, lymphoma, Hodgkin's disease, and colonic carcinoma.
  • disorders selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, bullous pemphigoid, helminthic parasitic infections, allergic co
  • the present invention provides a method for treating or preventing disorders selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, bullous pemphigoid, allergic colitis, eczema, conjunctivitis, familial eosinophilia, eosinophilic cellulitis, eosinophilic pneumonias, eosinophilic fasciitis, and eosinophilic gastroenteritis.
  • disorders selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, bullous pemphigoid, allergic colitis, eczema, conjunctivitis, familial eosinophilia, eosinophilic cellulitis, eosinophilic pneumonias, eosinophilic fasciitis, and eosinophilic gastroenteriti
  • the present invention provides a method for treating or preventing disorders selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, and eczema.
  • the present invention provides a method for treating or preventing disorders selected from asthma.
  • the present invention provides a method for treating or preventing disorders selected from allergic rhinitis.
  • the present invention provides a method for treating or preventing disorders selected from atopic dermatitis . In another embodiment, the present invention provides a method for treating or preventing disorders selected from inflammatory bowel diseases.
  • the present invention provides a method of modulating the chemokine receptor CCR-3 , comprising administration of an effective amount of a compound of formula (I) :
  • M is absent or selected from CH 2 , CHR 5 , CHR 13 , CR 13 R 13 , and CR 5 R 13 ;
  • Q is selected from CH 2 , CHR 5 , CHR 13 , CR 13 R 13 , and CR 5 R 13 ;
  • J and K are independently selected from CH 2 , CHR 5 , CHR 6 , CR 6 R 6 and CR 5 R 6 ;
  • L is selected from CHR 5 and CR 5 R 6 ;
  • J is selected from CH 2 , CHR 5 , CHR 13 , and CR 5 R 13 ;
  • Z is selected from O and S
  • E is -(CR 7 R 8 )-(CR 9 R 10 ) v -(CR 11 R 12 )-;
  • R 1 and R 2 are independently selected from H, C ⁇ _ 8 alkyl, C 3 _s alkenyl, C 3 .- 8 alkynyl, (CH 2 ) r C 3 -g cycloalkyl, and a (CH 2 ) r ⁇ c 3-io carbocyclic residue substituted with 0-5 R a ;
  • R a is selected from C ⁇ _ 4 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, (CH 2 ) r C 3 _g cycloalkyl, Cl, Br, I, F, (CF 2 ) r CF 3 , N0 2 , CN, (CH 2 ) r NR b R b , (CH 2 ) r OH, (CH 2 ) r OR c , (CH 2 ) r SH, (CH 2 ) r SR c , (CH 2 ) r C(0)R b , (CH 2 ) r C (0) NR b R b , (CH 2 ) r NR b C(0)R b , (CH 2 ) r C(0)OR b , (CH 2 ) r OC (0) R c ,
  • R b at each occurrence, is selected from H, Ci-g alkyl, C 3 _g cycloalkyl, and phenyl;
  • R c at each occurrence, is selected from C ⁇ _g alkyl, C 3 -g cycloalkyl, and phenyl;
  • R 2 and R 3 join to form a 5, 6, or 7-membered ring substituted with 0-3 R ;
  • R 3 is selected from a (CR 3 'R 3 ") r _ 3 - ⁇ o carbocyclic residue substituted with 0-5 R 15 and a (CR 3 'R 3 ") r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 15 ;
  • R 3 ' and R 3 " are selected from H, C ⁇ _g alkyl, (CH 2 ) r C 3 -g cycloalkyl, and phenyl;
  • R 4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C _ alkyl, C3-8 alkenyl, C3- 8 alkynyl, (CH 2 ) r C3- 6 cycloalkyl, (CH 2 ) q C (0)R b , (CH 2 ) q C (0)NR a R 4a# , (CH2) q C(0)OR 4b , and a (CH 2 ) r -C 3 - ⁇ o carbocyclic residue substituted with 0-3 R c ;
  • R a and R a ' are selected from H, C ⁇ _g alkyl, (CH 2 ) r 3 - cycloalkyl, and phenyl;
  • R b at each occurrence, is selected from C ⁇ _g alkyl, C 3 _ 8 alkenyl, (CH 2 ) r 3 -g cycloalkyl, C 3 _ 8 alkynyl, and phenyl ;
  • R c is selected from C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, C 3 -g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 )rCF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, (CH 2 ) r OH, (CH 2 ) r SCi_ 5 alkyl, (CH 2 ) r NR a R a ' , and (CH 2 ) r phenyl;
  • R 4 joins with R 7 , R 9 , or R 11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 R a ;
  • R 5 is selected from a (CR 5 'R 5 ") t -C 3 - ⁇ o carbocyclic residue substituted with 0-5 R 16 and a (CR 5 'R 5 ") t -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 16 ;
  • R 5 ' and R 5 " are selected from H, C ⁇ _ alkyl, (CH 2 ) r C 3 -g cycloalkyl, and phenyl;
  • R 6 is selected from C ⁇ _g alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, (CH 2 ) r C 3 -g cycloalkyl, (CF 2 ) r CF 3 , CN, (CH 2 ) r NR 6a R 6a ' ; (CH 2 ) r OH, (CH 2 ) r OR 6 , (CH 2 ) r SH, (CH 2 ) r SR 6 , (CH 2 ) r C(0)OH, (CH 2 ) r C (0) R 6b , (CH 2 ) r C(0)NR 6a R 6a ', (CH 2 ) r NR 6d C(0)R 6a , (CH 2 ) r C (0) 0R 6b , (CH 2 ) r 0C(0)R 6 , (CH 2 ) r S(0) p R 6b , (CH 2 ) r S(0) p R 6b ,
  • R 6a and R 6a ' are selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, and phenyl substituted with 0-3 R 6c.
  • R 6b at each occurrence, is selected from C ⁇ _g alkyl, C 3 _ cycloalkyl, and phenyl substituted with 0-3 R 6c ;
  • R 6c is selected from C ⁇ _g alkyl, C 3 _g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, (CH 2 ) r 0H, (CH 2 ) r SC ⁇ _ 5 alkyl, and (CH 2 ) r NR 6d R 6d ;
  • R 6d at each occurrence, is selected from H, C ⁇ _g alkyl, and C 3 - cycloalkyl;
  • R 7 is selected from H, Ci-g alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) q OH, (CH 2 ) q SH, (CH 2 ) q OR d , (CH 2 ) q SR 7d , (CH 2 ) q NR 7a R a ', (CH 2 ) r C(0)OH, (CH 2 ) r C (0) R 7 , (CH 2 ) r C (O) NR 7a R 7a ' , (CH 2 ) q NR 7a C (0) R 7b ,
  • R 7b is selected from C ⁇ _g alkyl, C 3 _ 8 alkenyl, C 3 _ 8 alkynyl, a (CH 2 ) r -C 3 _g carbocyclic residue substituted with 0-2 R 7e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 7e ;
  • R 7d is selected from C ⁇ _g alkyl, C 3 _ 8 alkenyl, C 3 _ 8 alkynyl, and a C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R 7c ;
  • R 7e at each occurrence, is selected from C ⁇ _g alkyl, C _s alkenyl, C _s alkynyl, C 3 - cycloalkyl, Cl, F, Br, I,
  • R 7f at each occurrence, is selected from H, Ci-g alkyl, and 3 -g cycloalkyl;
  • R 8 is selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, and (CH 2 ) r phenyl substituted with 0-3 R 8a ;
  • R 8a is selected from C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, C 3 _ cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OCi_ 5 alkyl, OH, SH, (CH 2 ) r SC ⁇ _ 5 alkyl, (CH 2 ) r NR 7f R 7f , and (CH 2 ) r phenyl ;
  • R 8b is selected from H, C ⁇ _g alkyl, C 3 - cycloalkyl, OH, CN, and (CH 2 ) r -phenyl ;
  • R 9 is selected from H, C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, F, Cl, Br, I, N0 2 , CN, (CH 2 ) q OR 9d , (CH 2 ) q SR 9d , (CH 2 ) r NR 9a R 9a ', (CH 2 ) r C(0)OH, (CH 2 ) r C (0) R 9b , (CH 2 ) r NR 9a C(0)R 9a , (CH 2 ) r NR 9a C(0)H, (CH 2 ) r NR 9a C (0) NHR 9a , (CH 2 ) r C(0)OR 9a , (CH 2 ) r OC(0)R , (CH 2 ) r S (0) p R 9b , (CH 2 ) r S(0) 2 NR 9a R 9a ', (CH 2 ) r NR 9a S(0) 2 R 9
  • R 9a and R 9a ' are selected from H, C ⁇ _g alkyl, C 3 _ 8 alkenyl, C 3 _ 8 alkynyl, a (CH ) r -C 3 - ⁇ 0 carbocyclic residue substituted with 0-5 R 9e , and a (CH ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 9e ;
  • R 9a and R 9a ' along with the N to which they are attached, join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 9 ⁇ , 0, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R 9b is selected from C ⁇ _g alkyl, C 3 - 8 alkenyl, C 3 _ 8 alkynyl, a (CH 2 ) r -C 3 _g carbocyclic residue substituted with 0-2 R 9e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 9e ;
  • R 9c is selected from C ⁇ _g alkyl, C 2 _ 8 alkenyl, C 2 _s alkynyl, (CH 2 ) r C 3 _g cycloalkyl, Cl, Br, I, F, (CF 2 ) r CF 3 , N0 2 , CN, (CH 2 ) r NR 9f R 9 f , (CH 2 ) r OH, (CH 2 ) r 0Ci- 4 alkyl, (CH 2 ) r SC 1 _ 4 alkyl, (CH 2 ) r C (0) OH, (CH 2 ) r C(0)R 9b , (CH 2 ) r C(0)NR 9f R 9f , (CH 2 ) r NR 9f C (0) R 9a , (CH 2 ) r C(0)OCi_ 4 alkyl, (CH 2 ) r 0C (0) R 9b , (CH 2 ) r C(
  • R 9d is selected from C ⁇ _g alkyl, C 3 -g alkenyl, C 3 -g alkynyl, a C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R 9c , and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-3 R 9c ;
  • R 9e is selected from C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 -s alkynyl, (CH 2 ) r C 3 -g cycloalkyl, Cl, F, Br, I, CN, N0 , (CF 2 ) r CF 3 , (CH 2 ) r OCi_ 5 alkyl, OH, SH, (CH 2 ) r SCi- 5 alkyl,' (CH ) r NR 9f R 9f , and (CH 2 )
  • R 9f at each occurrence, is selected from H, C ⁇ _g alkyl, and C 3 _ cycloalkyl;
  • R 9 ⁇ is selected from H, C ⁇ _g alkyl, C 3 -6 cycloalkyl, (CH 2 ) r phenyl, C(0)R 9f , C(0)OR 9h , and S ⁇ 2R 9h ;
  • R 9h at each occurrence, is selected from C ⁇ _ 5 alkyl, and C 3 _g cycloalkyl;
  • R 10 is selected from H, C ⁇ _g alkyl, C 2 _s alkenyl, C 2 - 8 alkynyl, F, Cl, Br, I, N0 2 , CN, (CH 2 ) q OR 10d , (CH 2 ) q SR 10d , (CH 2 ) r NR 10a R 10a ', (CH 2 ) r C (0) OH,
  • R 10a and R 10a ' are selected from H, C ⁇ _g alkyl, C _ 8 alkenyl, C 3 _ 8 alkynyl, a (CH 2 ) r -C 3 - ⁇ 0 carbocyclic residue substituted with 0-5 R 10e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 10e ;
  • R 10a and R 10a ' along with the N to which they are attached, join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 10 ⁇ , 0, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R 10b is selected from C _g alkyl, C 3 .- 8 alkenyl, C 3 _ 8 alkynyl, a (CH 2 ) r _ C 3 -g carbocyclic residue substituted with 0-2 R 10e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 10e ;
  • R 10c is selected from C ⁇ _g alkyl, C 2 _ 8 alkenyl, C 2 _s alkynyl, (CH 2 ) r C 3 -g cycloalkyl, Cl, Br, I, F, (CF 2 ) r CF 3 , N0 2 , CN, (CH 2 ) r NR 10f R 10f , (CH 2 ) r OH, (CH 2 ) r OCi_ 4 alkyl, (CH 2 ) r SC !
  • R 10d is selected from C ⁇ _g alkyl, C 3 _g alkenyl, C 3 - alkynyl, a C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R 10c , and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-3 R 10c ;
  • R 10e is selected from C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 _s alkynyl, (CH 2 ) r C 3 -g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r 0C ⁇ _ 5 alkyl, OH, SH,
  • R 10f is selected from H, Ci-g alkyl, and C 3 - cycloalkyl;
  • R lOg is selected from H, C ⁇ _g alkyl, C 3 _ cycloalkyl, (CH 2 ) r phenyl, C(O)R 10f , C(O)OR 10h , and SO 2 R 10h ;
  • R 10h at each occurrence, is selected from C ⁇ _ 5 alkyl, and C 3 _g cycloalkyl;
  • R 9 on adjacent carbon atoms form a bond, thereby forming a double bond, or R 9 and R 10 on adjacent carbon atoms each form a bond thereby forming a triple bond;
  • R 11 is selected from H, C ⁇ _g alkyl, C _ 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) q 0H, (CH 2 ) q SH, (CH 2 ) q OR lld , (CH 2 ) q SR lld , (CH 2 ) q NR lla R lla ', (CH 2 ) r C(0)0H, (CH 2 ) r C (0) R ll , (CH 2 )rC(0)NR lla R lla ', (CH 2 ) q NR lla C (O) R lla , (CH 2 ) q 0C(0)NR lla R lla ', (CH 2 ) q NR lla C (O) 0R llb ,
  • R lla and R lla ' are selected from H, Ci-g alkyl, C3_ 8 alkenyl, C 3 _s alkynyl, a (CH 2 ) r -C 3 - ⁇ o carbocyclic residue substituted with 0-5 R lle , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R lle ;
  • R lla and R lla ' join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 11 ⁇ , 0, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R llb at each occurrence, is selected from C ⁇ _g alkyl, C 3 _ 8 alkenyl, C 3 - 8 alkynyl, a (CH 2 ) r -C 3 _g carbocyclic residue substituted with 0-2 R lle , and a (CH 2 ) r -"5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R lle ;
  • R llc at each occurrence, is selected from C ⁇ _g alkyl, C 2 _ 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) r C 3 _g cycloalkyl, Cl, Br, I, F, (CF 2 ) r CF 3 , N0 2 , CN, (CH 2 ) r NR llf R 11£ , (CH 2 ) r 0H,
  • R lld is selected from methyl, CF 3 , C 2 -g alkyl substituted with 0-3 R lle , C _g alkenyl, C 3 - alkynyl, and a 0 3 - 10 carbocyclic residue substituted with 0-3 R llc ;
  • R lle at each occurrence, is selected from C ⁇ _g alkyl, C 2 - 8 alkenyl, C - 8 alkynyl, C 3 -g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r 0Ci_ 5 alkyl, OH, SH, (CH 2 ) r SC 1 . 5 alkyl, (CH 2 ) r NR llf R llf , and (CH 2 ) r pheny1 ;
  • R llf at each occurrence, is selected from H, Ci-g alkyl, and C 3 _g cycloalkyl;
  • R 11 ⁇ is selected from H, C ⁇ _g alkyl, C 3 _ cycloalkyl, (CH 2 ) r phenyl, C(0)R llf , C(0)OR llh , and S0 2 R llh ;
  • R llh at each occurrence, is selected from C ⁇ _g alkyl, and c 3 -g cycloalkyl;
  • R 12 is selected from H, C ⁇ -g alkyl, (CH 2 ) q 0H, (CH 2 ) r C 3 -g cycloalkyl, and (CH 2 ) t phenyl substituted with 0-3 R 12a ;
  • R 12 is selected from C ⁇ _g alkyl, C 2 - 8 alkenyl, C _ 8 alkynyl, C 3 - cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OCi- 5 alkyl, OH, SH, (CH 2 ) r SCi_ 5 alkyl, (CH 2 ) r NR 9f R 9f , and (CH 2 ) r phenyl ;
  • R 11 and R 12 join to form a cyclic structure wherein the cyclic structure is selected from C 3 _ ⁇ o carbocycle, a 5-6-membered lactone or lactam, or a 4-6-membered saturated heterocycle containing 1-2 heteroatoms selected from 0, S, and R 11 ⁇ and optionally fused with a benzene ring or a 6- membered aromatic heterocycle;
  • R 9 and R 10 , or R 11 and R 12 join to form the cyclic structure, or R 9 on adjacent carbon atoms form a bond, thereby forming a double bond, or R 9 and R 10 on adjacent carbon atoms each form a bond thereby forming a triple bond when v is equal to 2 ;
  • R 13 at each occurrence, is selected from C ⁇ _g alkyl, C 2 _8 alkenyl, C 2 _ 8 alkynyl, C 3 -g cycloalkyl, (CF 2 ) W CF 3 , (C ⁇ J g NR 13 ⁇ 133 ', (CH 2 ) q OH, (CH 2 ) q OR 13b , (CH 2 ) q SH, (CH 2 ) q SR 13b , (CH 2 ) w C(0)OH, (CH 2 ) W C (0) R 1 b , (CH 2 ) w C(0)NR 13a R 13a ⁇ (CH 2 ;
  • R 13 and R 13a ' are selected from H, C ⁇ _g alkyl, C3_g cycloalkyl, and phenyl substituted with 0-3 R 13c.
  • R 13b at each occurrence, is selected from C ⁇ _g alkyl, C3_ cycloalkyl, and phenyl substituted with 0-3 R 13c ;
  • R 13c is selected from C ⁇ _g alkyl, C3-g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, (CH 2 ) r 0H, (CH 2 ) r SC ⁇ -5 alkyl, and (CH 2 ) r NR 13d R 13d ;
  • R 13d at each occurrence, is selected from H, C ⁇ _g alkyl, and C3_ cycloalkyl;
  • R 15 at each occurrence, is selected from C ⁇ _s alkyl, (CH 2 ) r C3-g cycloalkyl, Cl, Br, I, F, N0 2 , CN,
  • R' at each occurrence, is selected from H, C ⁇ _g alkyl, C 2 _ 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) r C 3 _g cycloalkyl, and (CH 2 ) r phenyl substituted with R 15e ;
  • R 15a and R 15a ' are selected from H, C ⁇ _g alkyl, C 3 _ 8 alkenyl, C 3 _ 8 alkynyl, a (CH 2 ) r -C 3 - ⁇ 0 carbocyclic residue substituted with 0-5 R 15e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 R 15e ;
  • R 15a and R 15a ' along with the N to which they are attached, join to form a 5-6 membered heterocyclic system containing 1-2 heteroatoms selected from NR 15 ⁇ , O, and S and optionally fused with a benzene ring or a 6-membered aromatic heterocycle;
  • R 15b is selected from C ⁇ _ alkyl, C 3 _s alkenyl, C 3 - 8 alkynyl, a (CH 2 ) r -C 3 _g carbocyclic residue substituted with 0-3 R 15e , and (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 R 15e ;
  • R 15d is selected from C 3 _ 8 alkenyl, C 3 - 8 alkynyl, methyl, CF 3 , C 2 _g alkyl substituted with 0-3 R 15e , a (CH 2 ) r -C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R 15e , and a (CH 2 ) r 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R 15e ;
  • R 15e is selected from C ⁇ _g alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, (CH 2 ) r C 3 _g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OCi_ 5 alkyl, OH, SH, (CH 2 ) r SCi_ 5 alkyl, (CH 2 ) r NR 15f R 15f , and (CH 2 ) r phenyl ;
  • R 15f is selected from H, Ci-g alkyl, C 3 -g cycloalkyl, and phenyl;
  • R l5g i s selected from H, C ⁇ _g alkyl, C 3 _g cycloalkyl, (CH 2 ) r phenyl, C(0)R 15f , C(0)OR 15f , and S ⁇ 2R 15f ;
  • R 16 is selected from C ⁇ _ 8 alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) r 3 - cycloalkyl, Cl, Br, I, F, N0 2 , CN, (CHR') r NR 16a R 16a ', (CHR') r OH, (CHR') r O(CHR') r R 16d , (CHR') r SH, (CHR' ) r C (O) H, (CHR' ) r S (CHR' ) r R 16d , (CHR' ) r C (O) OH, (CHR' ) r C (0) (CHR' ) r R 16b , (CHR' ) r C (0) NR 16a R 16 ' , (CHR' ) r NR 16f C (0) (CHR' ) r R 16b , (CHR' )
  • R i6 a and R 16a ' are selected from H, C ⁇ -g alkyl, C 3 _ 8 alkenyl, C 3 _ 8 alkynyl, a (CH 2 ) r -C 3 - ⁇ o carbocyclic residue substituted with 0-5 R 16e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 R 16e ;
  • R 16b at each occurrence, is selected from C _g alkyl, C 3 _s alkenyl, C 3 _ 8 alkynyl, a (CH 2 ) r C 3 -g carbocyclic residue substituted with 0-3 R 16e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R 16e ;
  • R 16d is selected from C 3 _s alkenyl, C 3 _ 8 alkynyl, methyl, CF 3 , C 2 - alkyl substituted with 0-3 R 16e , a (CH 2 ) r -C 3 _ ⁇ o carbocyclic residue substituted with 0-3 R 16e , and a (CH 2 ) r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R 16e ;
  • R 16e is selected from C ⁇ _g alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) r c 3 -g cycloalkyl, Cl, F, Br, I, CN, N0 2 , (CF 2 ) r CF 3 , (CH 2 ) r OC ⁇ _ 5 alkyl, OH, SH, (CH 2 ) r SC ⁇ - 5 alkyl, (CH 2 ) r NR 16f R 16f , and (CH 2 ) r phenyl ;
  • R 16f at each occurrence, is selected from H, C _ 5 alkyl, and C 3 _g cycloalkyl, and phenyl;
  • v is selected from 0, 1, and 2;
  • t is selected from 1 and 2 ;
  • w is selected from 0 and 1;
  • r is selected from 0, 1, 2, 3, 4, and 5;
  • q is selected from 1, 2, 3, 4, and 5;
  • p is selected from 0, 1, and 2.
  • the present invention provides a method for treating or preventing disorders selected from eczema.
  • R 15 ' is selected from C 2 - 8 alkenyl, C 2 - 8 alkynyl, (CH 2 ) r C 3 -g cycloalkyl, (CHR') r SH, (CHR' ) 3 _ 5 C (O) H, (CHR' ) r S (CHR' ) r R 15d , (CHR') q C(0)OH, (CHR') g C(O) (CHR') q R 15 , (CHR' ) r C (0)NR 15a R 15a ' , (CHR') r NR 15f C(0) (CHR') r R 15b , (CHR' ) r OC (0) NR 15a R 15a ' ,
  • R 15 ' is selected from C 2 _s alkenyl, C 2 - 8 alkynyl, (CH 2 ) r 3 - cycloalkyl, (CHR') r SH, (CHR' ) 3 - 5 C (O)H, (CHR' ) r S (CHR' ) r R 15d , (CHR' ) r C (0) NR 15a R 15a ' , (CHR' ) r NR 15f C (O) (CHR' ) r R 15b , (CHR') r OC(0)NR 15a R 15a ', (CHR' ) r NR 15f C (0) O (CHR' ) r R 15 , (CHR' ) r C (0) O (CHR' ) r R 15d , (CHR' ) r OC (O) (CHR' ) r R 15b , (CHR''
  • R' (CHR') r phenyl substituted with 0-3 R 15e , and a (CH 2 ) r -5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 R 15e.
  • the compounds herein described may have asymmetric centers .
  • any variable e.g., R a
  • its definition at each occurrence is independent of its definition at every other occurrence.
  • R a e.g., R a
  • R a substituents and/or variables are permissible only if such combinations result in stable compounds.
  • C ⁇ _ 8 alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, examples of which include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec- butyl, t-butyl, pentyl, and hexyl.
  • C ⁇ _s alkyl is intended to include Ci, C 2 , C 3 , C 4 , C 5 , Cg, C 7 , and Cs alkyl groups.
  • Alkenyl is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like.
  • Alkynyl is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl, and the like.
  • C 3 _g cycloalkyl is intended to include saturated ring groups having the specified number of carbon atoms in the ring, including mono-, bi-, or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl in the case of C 7 cycloalkyl.
  • C 3 _g cycloalkyl is intended to include C 3 , C 4 , C 5 , and Cg cycloalkyl groups
  • Halo or "halogen” as used herein refers to fluoro, chloro, bromo, and iodo
  • the compounds of Formula I can also be quaternized by standard techniques such as alkylation of the piperidine or pyrrolidine with an alkyl halide to yield quaternary piperidinium salt products of Formula I.
  • Such quaternary piperidinium salts would include a counterion.
  • counterion is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like.
  • the term "piperidinium spirocycle or pyrrolidinium spirocycle” is intented to mean a stable spirocycle ring system, in which the two rings form a quarternary nitrogene at the ring junction.
  • 5-6-membered cyclic ketal is intended to mean 2, 2-disubstituted 1, 3-dioxolane or 2,2- disubstituted 1,3-dioxane and their derivatives.
  • “carbocycle” or “carbocyclic residue” is intended to mean any stable 3, 4, 5, 6, or 7-membered onocyclic or bicyclic or 7 , 8, 9, 10, 11, 12, or 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic.
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, ; [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4. O]bicyclodecane (decalin) , [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin) .
  • heterocycle or “heterocyclic system” is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7 , 8, 9, or 10- membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, 0 and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized.
  • the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure.
  • the heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another.
  • aromatic heterocyclic system is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, 0 and S.
  • heterocycles include, but are not limited to, lH-indazole, 2-pyrrolidonyl, 2H, 6H-1, 5, 2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H- quinolizinyl, 6H-1, 2 , 5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzi idazalonyl, carbazolyl, 4aH-carbazolyl, ⁇ -carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydro
  • oxazolyl oxazolidinylperimidinyl, phenanthridinyl , phenanthroliny1 , phenarsazinyl , phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl , pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyr
  • Preferred heterocycles include, but are not limited to, pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiaphenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoidolyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pyrrazolyl, 1,2,4- triazolyl, 1, 2 , 3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles .
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non- toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxybenzoic , fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic,
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
  • prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc..) the compounds of the present invention may be delivered in prodrug form.
  • the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same.
  • Prodrugs are intended to include any covalently bonded carriers which release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
  • Prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention.
  • Solid compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent .
  • the compounds of Formula I can be prepared using the reactions and techniques described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention.
  • halide Cl, Br, I
  • KI can also be added to facilitate the displacement, provided the solvent is suitable, such as an alcohol, 2-butanone, DMF or DMSO, amongst others.
  • the displacement can be performed at room temperature to the reflux temperature of the solvent .
  • the protecting group is subsequently removed to yield amine 4.
  • Protecting groups include phthalimide which can be removed by hydrazine, a reaction familiar to one skilled in the art; bis-BOC which can be removed by either TFA or HC1 dissolved in a suitable solvent, both procedures being familiar to one skilled in the art; a nitro group instead of an amine which can be reduced to yield an amine by conditions familiar to one skilled in the art; 2,4-dimethyl pyrrole (S. P.
  • Activation of imidazolide intermediates also facilitates urea formation (Bailey, R. A., et al . , Tet. Lett. 1998, 39, 6267-6270) .
  • the urea forming reactions are done in a non- hydroxylic inert solvent such as THF, toluene, DMF, etc., at room temperature to the reflux temperature of the solvent and can employ the use of an acid scavenger or base when necessary such as carbonate and bicarbonate salts, triethylamine, DBU, Hunigs base, DMAP, etc.
  • Substituted pyrrolidines and piperidines 1 can either be obtained commercially or be prepared as shown in Scheme 2.
  • N-benzylpiperid-3-one 16 can be debenzylated and protected with a BOC group employing reactions familiar to one skilled in the art.
  • Subsequent Wittig reaction followed by reduction and deprotection yields piperidine 20 employing reactions familiar to one skilled in the art.
  • Substituted pyrrolidines may be made by a similar reaction sequence.
  • Other isomers and analogs around the piperidine ring can also be made by a similar reaction sequence.
  • Chiral pyrrolidines/piperidines can be synthesized via asymmetric hydrogenation of 18 using chiral catalysts (see Parshall, G.W. Homogeneous Catalysis, John Wiley and Sons, New York: 1980, pp. 43-45; Collman, J.P., Hegedus, L.S. Principles and Applications of Organotransition Metal Chemistry, University Science Books, Mill Valley, CA, 1980, pp. 341-348).
  • reaction of thiourea 1 with amines in the presence of triethanolamine and "lac sulfur" which facilitates the removal of H 2 S yields substituted guanidines 23. (K. Ramadas, Tet. Lett. 1996, 37, 5161 and references therein) .
  • a method for introducing substituents in linkage E is that of A. Chesney et al . (Syn. Comm. 1990, 20 (20), 3167- 3180) as shown in Scheme 4.
  • Michael reaction of pyrrolidine or piperidine 1 with Michael acceptor 26 yields intermediate 27 which can undergo subsequent reactions in the same pot.
  • reduction yields alcohol 8 which can be elaborated to the amine 29 by standard procedures familiar to one skilled in the art. Some of these include mesylation or tosylation followed by displacement with NaN 3 followed by reduction to yield amine 29 .
  • Another route as depicted in Scheme 4 involves reaction with diphenylphosphoryl azide followed by reduction of the azide to yield amine 29.
  • the mesylate or tosylate can also be displaced by other nucleophiles such as NH 3 , BOC 2 N ⁇ , potassium phthalimide, etc., with subsequent deprotection where necessary to yield amines 29.
  • 29 . can be converted to urea or thiourea 3_0 by procedures discussed for Scheme 1 or to the compounds of this invention by procedures previously discussed.
  • aldehyde 22 may be reacted with a lithium or a Grignard reagent 3_1 to yield alcohol adduct 32. This in turn can be converted to urea or thiourea 34 . in the same way as discussed for the conversion of 28 . to 30.
  • Scheme 5 shows that intermediate 3_6 can be extended via a Wittig reaction (A. Chesney, et al . Syn. Comm. 1990, 20 (20), 3167-3180) to yield 37.
  • This adduct can be reduced catalytically to yield 38 . or by other procedures familiar to one skilled in the art.
  • Alkylation yields 39 followed by saponification and Curtius rearrangement (T. L. Capson and C. D. Poulter, Tet. Lett., (1984) 25, 3515-3518) followed by reduction of the benzyl protecting group yields amine 40 which can be elaborated further as was described earlier in Scheme 1 and elsewhere in this application to make the compounds of this invention.
  • OH group can undergo synthetic transformations which are familiar to one skilled in the art and which will be discussed in much detail later on in the application.
  • Chiral auxilliaries can also be used to introduce stereo- and enantioselectivity in these aldol condensations, procedures which are familiar to one skilled in the art.
  • compound 48 can also undergo the analogous reactions just described to form cyclopropylamine 5_0 which can be further elaborated into the compounds of this invention as described previously.
  • Compound 48. may be synthesized by an alkylation reaction of pyrrolidine/piperidine 1 with bromide 47 in an inert solvent employing the conditions as described for the alkylation of 2 onto 1 in Scheme 1.
  • ketone 57 which may undergo nucleophilic 1,2-addition with organometallic reagents such as alkyl- or aryllithiums, Grignards, or zinc reagents, with or without CeCl 3 (T. I amoto, et al., Tet. Lett. 1985, 26, 4763-4766; T. Imamoto, et al . , Tet. Lett. 1984, 25, 4233-4236) in aprotic solvents such as ether, dioxane, or THF to yield alcohol 58 . .
  • organometallic reagents such as alkyl- or aryllithiums, Grignards, or zinc reagents
  • CeCl 3 T. I amoto, et al., Tet. Lett. 1985, 26, 4763-4766; T. Imamoto, et al . , Tet. Lett. 1984, 25, 4233-4236
  • aprotic solvents such as
  • Epoxides disclosed by structure 54 may be synthesized enantio-selectively from amino acid starting materials by the methods of Dellaria, et al . J Med Chem 1987, 30 (11), 2137, and Luly, et al . J Org Chem 1987, 52 (8), 1487.
  • the carbonyl group of ketone 57 in Scheme 8 may undergo Wittig reactions followed by reduction of the double bond to yield alkyl, arylalkyl, heterocyclic-alkyl, cycloalkyl, cycloalkylalkyl, etc. substitution at that position, reactions that are familiar to one skilled in the art.
  • Wittig reagents can also contain functional groups which after reduction of the double bond yield the following functionality: esters (Buddrus, J. Angew Chem., 1968, 80), nitriles (Cativiela, C.et al . , Tetrahedron 1996, 52 (16), 5881-5888.), ketone (Stork, G.et al .
  • Scheme 9 summarizes the displacement chemistry and subsequent elaborations that can be used to synthesize the R 9 groups .
  • alcohol 55 . or 58 may be tosylated, mesylated, triflated, or converted to a halogen by methods familiar to one skilled in the art to produce compound 59.
  • carbon homologs of 55 or 58 where OH can be (CH ) r OH and it is also understood that these carbon homologs may have substituents on the methylene groups as well
  • a hydroxyl group may be converted to a bromide by CBr 4 and Ph 3 P (Takano, S. Heterocycles 1991, 32, 1587) .
  • CBr 4 and Ph 3 P Tetra-Br 4 and Ph 3 P
  • Compound 5_9 in turn may be displaced by a wide variety of nucleophiles as shown in Scheme 9 including but not limited to azide, cyano, malonate, cuprates, potassium thioacetate, thiols, amines, etc., all nucleophilic displacement reactions being familiar to one skilled in the art.
  • Nitrile 60 can be reduced with DIBAL to yield aldehyde . 61.
  • This aldehyde can undergo reduction to alcohol 62 with, for example, NaBH 4 which in turn can undergo all of the SN2 displacement reactions mentioned for alcohol 55 or 58.
  • Alcohol 62 is a one carbon homolog of alcohol 55 or 58.
  • Sulfones 72 can be converted to the corresponding sulfonamides 73. by the method of H.-C. Huang, E. et al., Tet. Lett. (1994) 35, 7201-7204 which involves first, treatment with base followed by reaction with a trialkylborane yielding a sulfinic acid salt which can be reacted with hydroxylamine-O-sulfonic acid to yield a sulfonamide.
  • Another route to sulfonamides involves reaction of amines with a sulfonyl chloride (G. Hilgetag and A.
  • the isothiouronium salt may be synthesized from the corresponding halide, mesylate or tosylate 5_9 via reaction with thiourea (for a discussion on the synthesis of sulfonyl chlorides see G. Hilgetag and A. Martini, ibid. , p. 670) .
  • the aldehyde 67 obtained from the Weinreb amide reduction can be reduced to the alcohol with NaBH 4 .
  • the aldehyde or ketone . 67 (or 61 or 61b for that matter) can undergo Wittig reactions as discussed previously followed by optional catalytic hydrogenation of the olefin.
  • This Wittig sequence is one method for synthesizing the carbocyclic and heterocyclic substituted systems at R 9 employing the appropriate carbocyclic or heterocyclic Wittig (or Horner-Emmons ) reagents.
  • the Wittig reaction may also be used to synthesize alkenes at R 9 and other functionality as well.
  • Ester 65 can also form amides 66 .
  • Alcohol . 68 . can be converted to ether . 69 by procedures familiar to one skilled in the art, for example, NaH, followed by an alkyliodide or by Mitsunobu chemistry (Mitsunobu, O. Synthesis, 1981, 1-28) .
  • Alcohol 55 or 58, 62 , or j68 can be acylated by procedures familiar to one skilled in the art, for example, by Schotten-Baumann conditions with an acid chloride or by an anhydride with a base such as pyridine to yield J_8 .
  • Halide, mesylate, tosylate or triflate 59 can undergo displacement with azide followed by reduction to yield amine 74 . a procedure familiar to one skilled in the art.
  • This amine can undergo optional reductive animation and acylation to yield 75 or reaction with ethyl formate (usually refluxing ethyl formate) to yield formamide 75..
  • Amine 74 can again undergo optional reductive amination followed by reaction with a sulfonyl chloride to yield J_6 , for example under Schotten- Baumann conditions as discussed previously.
  • This same sequence may be employed for amine 60a, the reduction product of nitrile 60 . . Tosylate 5_9 can undergo displacement with cuprates to yield 77 (Hanessian, S.; Thavonekham, B.; DeHoff, B.; J Org. Chem. 1989, 54, 5831).
  • Aldehyde .61 or its homologous extensions can be reacted with a carbon anion of an aryl (phenyl, naphthalene, etc.) or heterocyclic group to yield an aryl alcohol or a heterocyclic alcohol.
  • CeCl 3 may be added (T. Imamoto, et al . , Tet. Lett. 1985, 26, 4763-4766; T. Imamoto, et al . , Tet. Lett. 1984, 25, 4233-4236). This alcohol may be reduced with Et 3 SiH and TFA (J. Org. Chem. 1969, 34, 4; J. Org. Chem.
  • aryl and heterocyclic anions may also be alkylated by 59 (or its carbon homolog) to yield compounds where R 9 contains an aryl or heterocyclic group.
  • Compound 59 . or its carbon homologs may be alkylated by an alkyne anion to produce alkynes at R 9 (see R.C. Larock, Comprehensive Organic Transformations, New York, 1989, VCH Publishers, p 297) .
  • carboxaldehyde .61 or its carbon homologs can undergo 1,2-addition by an alkyne anion (Johnson, A.W. The Chemistry of Acetylenic Compounds. V. 1.
  • Nitro groups can be introduced by displacing bromide 59. (or its carbon homologs) with sodium nitrite in DMF (J.K. Stille and E.D. Vessel J. Org. Chem. 1960, 25, 478-490) or by the action of silver nitrite on iodide 59 or its carbon homologs (Org. Syntheses 34, 37-39) .
  • R 9 is either in its final form or in a suitable protected precursor form.
  • This electrophile can be a carbon-based electrophile, some examples being formaldehyde to introduce a CH 2 OH group, an aldehyde or a ketone which also introduces a one-carbon homologated alcohol, ethylene oxide (or other epoxides) which introduces a -CH 2 CHOH group (a two-carbon homologated alcohol), an alkyl halide, etc., all of which can be later elaborated into R 9 .
  • It can also be an oxygen-based electrophile such as MCPBA, Davis' reagent (Davis, F. A. ; Haque, M.
  • Weinreb amide %2 can be synthesized via Michael-type addition of 1 to alpha,beta-unsaturated Weinreb amide .83.. Subsequent reaction with a Grignard reagent forms ketone 85..
  • This ketone can also be synthesized in one step directly from 1 and alpha, beta- unsaturated ketone 84 using the same procedure.
  • This ketone may be reduced with LAH, NaBH 4 or other reducing agents to form alcohol 86 . .
  • ketone .85 can be reacted with an organolithium or Grignard reagents to form tertiary alcohol .87 .
  • ester .80 can be directly reduced with LiBH 4 or LAH to yield primary alcohol 88 . . SCHEME 10
  • Alcohols 86, 87 , and 8 can all be tosylated, esylated, triflated, or converted to a halogen by methods discussed previously and displaced with an amine nucleophile such as azide, diphenylphosphoryl azide (with or without DEAD and P ⁇ 1 3 P) , phthalimide, etc. as discussed previously (and which are familiar to one skilled in the art) and after reduction (azide) or deprotection with hydrazine (phthalimide) , for example, yield the corresponding amines. These can then be elaborated into the compounds of this invention as discussed previously. Ketone 85. can also be converted into imine 89 .
  • R 7-12 in Scheme 10 can be in their final form or in precursor form which can be elaborated into final form by procedures familiar to one skilled in the art.
  • amino group can be reacted with an isocyanate, an isothiocyanate, a carbamoyl chloride, or any reagent depicted in Scheme 1 to form 95 which can be alkylated with 1 to form the compounds of this invention.
  • amine 1 might have to be activated with Lewis acids in order to open the epoxide ring (Fujiwara, M. ; Imada, M. ; Baba, A.; Matsuda, H .; Tetrahedron Lett 1989, 30, 739; Caron, M. ; Sharpless, K. B.; J Org Chem 1985, 50, 1557) or 1 has to be deprotonated and used as a metal amide, for example the lithium amide (Gorzynski-Smith, J. ; Synthesis 1984 (8), 629) or MgBr amide (Carre, M. C; Houmounou, J. P.; Caubere, P.; Tetrahedron Lett 1985, 26, 3107) or aluminum amide (Overman, L. E. ; Flippin, L. A. ; Tetrahedron Lett 1981, 22, 195).
  • Lewis acids for example the lithium amide (Gorzynski-Smith, J. ; Synthesis 1984 (8),
  • the quaternary salts (where R 4 is present as a substituent) of pyrrolidines and piperidines can be synthesized by simply reacting the amine with an alkylating agent, such as methyl iodide, methyl bromide, ethyl iodide, ethyl bromide, ethyl or methyl bromoacetate, bromoacetonitrile, allyl iodide, allylbromide, benzyl bromide, etc. in a suitable solvent such as THF, DMF, DMSO, etc . at room temperature to the reflux temperature of the solvent.
  • an alkylating agent such as methyl iodide, methyl bromide, ethyl iodide, ethyl bromide, ethyl or methyl bromoacetate, bromoacetonitrile, allyl iodide, allylbromide, benzyl bromid
  • Spiroquaternary salts can be synthesized in a similar manner, the only difference being that the alkylating agent is located intramolecularly as shown in Scheme 12. It is understood by one skilled in the art that functional groups might not be in their final form to permit cyclization to the quaternary ammonium salt and might have to be in precursor form or in protected form to be elaborated to their final form at a later stage.
  • the leaving groups represented by X in Scheme 12 may equal those represented in Scheme 1, but are not limited thereto.
  • N-oxides of pyrrolidines and piperidines can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) . This simply entails reacting the pyrrolidine or piperidine with MCPBA, for example, in an inert solvent such as methylene chloride.
  • Multisubstituted pyrrolidines and piperidines may be synthesized by the methods outlined in Scheme 13 .
  • thermodynamic or kinetic conditions yield regioselectively alkylated products (for a discussion on thermodynamic vs. kinetic alkylations see H. House Modern Synthetic Reactions, W. A. Benjamin, Inc. (Menlo Park, CA: 1972) chapter 9) .
  • the amine 109 an then be elaborated into the compounds of this invention by methods discussed previously (Scheme 1) .
  • the carbonyl- containing intermediate 107 in Scheme 13 can also be reduced to the methylene analog via a Wolff-Kishner reduction and modifications thereof, or by other methods familiar to one skilled in the art.
  • the carbonyl group can also be reduced to an OH group, which can undergo all of the reactions described in Scheme 9 to synthesize the R6 groups .
  • This piperidine or pyrrolidine can be deprotected and elaborated to the compounds of this invention by methods discussed earlier.
  • 3-carboethoxypiperidine 110 may be BOC-protected and alkylated employing a base such as LDA, KHMDS, LHDMS, etc., in THF, ether, dioxane, etc. at -78 °C to room temperature, and an alkylating agent
  • R 5 * R 5 or a precursor thereof
  • the OH may be reduced by the method of Barton (Barton, D. H. R. ; Jaszberenyi, J. C. Tet. Lett. 1989, 30, 2619 and other references therein) .
  • the alcohol can also be displaced with dialkyllithium cuprates (not shown) (Hanessian, S . ; Thavonekham, B.; DeHoff, B.; J Org. Chem. 1989, 54, 5831) .
  • Deprotection if necessary yields 120 which may be elaborated as described previously into the compounds of this invention.
  • a method for the alkylation of alkyl groups, arylalkyl groups, allylic groups, propargylic groups, etc., and a variety of other electrophiles onto the pyrrolidinyl and/or piperidinyl alpha-carbons (alpha to the ring nitrogen atom) is represented by the work of Peter Beak, et al . as shown in Scheme 15. It is understood by one skilled in the art that the R 5 and R 13 groups are either in their precursor, protected, or final form. Only one R 5 group is shown to be substituted on piperidine/pyrrolidine 121. However it is understood by one skilled in the art that additional functionality may be present on the ring in either precursor, protected, or final form.
  • Scheme 17 describes another method for the synthesis of compounds where R 9 and R 10 are taken together to form cycloalkyl groups .
  • alcohols can then be activated either by conversion to a halide or to a mesylate, tosylate or triflate by methods familiar to one skilled in the art and as discussed previously, and then alkylated with pyrrolidine/piperidine 1 by the conditions described in Scheme 1 to yield 135. Subsequent deprotection yields amine 136 which can be elaborated to the compounds of this invention as described previously.
  • alcohol 133 can be oxidized to the aldehyde and then reacted with R 7or8 MgBr or R 7or8 Li with or without CeCl 3 to yield the corresponding alcohol 133 where instead of -CH 2 OH, we would have -CHR 7or8 OH.
  • This oxidation-1, 2-addition sequence may be repeated to yield a tertiary alcohol .
  • the alcohol may then be tosylated, mesylated, triflated, or converted to Cl, Br, or I by procedures familiar to one skilled in the art to yield 134 and then displaced with pyrrolidine/piperidine 1 to yield 135.
  • Subsequent deprotection yields 136 which may undergo elaboration to the compounds of this invention as discussed previously.
  • a method to introduce cycloalkyl groups at R 1:L R 12 is shown in Scheme 18. Protection of the nitrogen of compounds 137 which are commercially available yields 138 (the protecting group may be BOC, CBZ, or any other compatible protecting group) by procedures familiar to one skilled in the art. Esterification by any one of a number procedures familiar to one skilled in the art (for example A. Hassner and V. Alexanian, Tet. Lett, 1978, 46, 4475-8) followed by reduction with DIBAL (or alternatively reduction to the alcohol with, for example, LiBH , followed by Swern oxidation (op. cit.)) yields aldehyde 139. One carbon homologation via the Wittig reaction followed by hydrolysis of the vinyl ether yields aldehyde 141.
  • Reductive animation (Abdel-Magid, A. F., et al . Tet. Lett. 1990, 31, (39) 5595-5598) yields 142 followed by deprotection yields amine 143 which can be elaborated to the compounds of this invention by the methods previously discussed.
  • aldehyde 139 can be reacted with R 9orio MgBr or R 9orio i w i t h or without CeCl 3 to yield an alcohol which can be oxidized to a ketone .
  • Aldehyde 141 (-CHCHO) or its monosubstituted analog synthesized above (-CHR 9orlo CHO) can undergo alkylation with 9o r l ⁇ ⁇ where X is as defined in Scheme 1 to yield compound 141 containing one or both of the R 9 and R 10 substituents alpha to the aldehyde group.
  • Alkylation can be performed using LDA or lithium bistrimethylsilyl amide amongst other bases in an inert solvent such as ether, THF, etc., at -78 °C to room temperature.
  • Aldehyde 141 (-CH 2 CHO)or its substituted analogs synthesized above (i.e., -CHR 9 R 10 CHO) can undergo reductive amination with 1 and subsequent elaboration to the compounds of this invention.
  • Aldehyde 141 (-CHCHO)or its substituted analogs synthesized above can undergo reductive amination with 1 and subsequent elaboration to the compounds of this invention.
  • -CHR 9 R 10 CHO can also undergo 1,2-addition with R 7or8 MgBr or R 7or8 Li to yield the corresponding alcohol - CH 2 CHR 7or8 OH or -CHR 9 R 10 CHR 7or8 OH.
  • the alcohol may then be tosylated, mesylated, triflated, or converted to Cl, Br, or I by procedures familiar to one skilled in the art and displaced with pyrrolidine/piperidine 1 to yield, after subsequent deprotection and elaboration, the compounds of this invention.
  • alcohol -CH CHR 7or8 OH or - CR 9 R 10 CHR 7or8 OH can be oxidized (i.e., Swern, op. cit.) to the ketone and reductively aminated with 1 and subsequently elaborated to the compounds of this invention.
  • alcohol -CH 2 CHR 7or8 OH or -CR 9 R 10 CHR 7or8 OH can be oxidized (i.e., Swern, op. cit.) to the ketone and reacted once more with R 7or8 MgBr or R 7or8 Li to yield the corresponding alcohol -CH 2 CR 7 R 8 OH or -CR 9 R 10 CR 7 R 8 OH.
  • CeCl 3 may be used together with the Grignard or lithium reagent.
  • the alcohol can again be tosylated, mesylated, triflated, or converted to Cl, Br, or I by procedures familiar to one skilled in the art and displaced with pyrrolidine/ piperidine 1 to yield, after subsequent deprotection and elaboration, the compounds of this invention.
  • each one of the R 7 , R 8 , R 9 , and R 10 groups may be introduced into compounds 141, 142 and 143 and and, of course, in the compounds of this invention, by the methods discussed above.
  • a method for the synthesis of N-substituted heterocycles at R 5 is shown in Scheme 19.
  • the heterocycle can be deprotonated with NaH or by other bases familiar to one skilled in the art, in a solvent such as DMF, THF, or another appropriate non-hydroxylic solvent and reacted with piperidine or pyrrolidine 143 at room temperature to the reflux temperature of the solvent. Deprotection and elaboration as described before yields compounds where R 5 contains an N-substituted heterocycle.
  • an acid scavenger such as K 2 C ⁇ 3 , KHCO 3 , Na 2 C ⁇ 3 , NaHC0 3 , amongst others, can be used in place of NaH, employing THF, DMF, or methyl ethyl ketone as solvents.
  • hydroxylic solvents may be used as well, such as methanol, ethanol , etc . from room temperature to the reflux temperature of the solvent.
  • Compound 143 as well as its other positional isomers are available, for example, from commercially available 4-hydroxymethylpiperidine, 2-, 3-, and 4-carboethoxypiperidine, L- or D-proline ethyl ester, or from methyl l-benzyl-5-oxo-3-pyrrolidinecarboxylate by methods familiar to one skilled in the art and as discussed previously in this application.
  • a method for the synthesis of C-substituted heterocycles at R 5 is shown in Scheme 20.
  • Many heterocycles such as the ones shown in Scheme 20, but not limited thereto, can be metallated with strong bases such as LDA, n-BuLi, sec-BuLi, t-BuLi, etc. to yield the corresponding anionic species.
  • These anions may also be generated via halogen-metal exchange employing n-BuLi, or other alkyllithium reagents. These reactions may be performed in THF, ether, dioxane, DME, benzene, etc. at -78 °C to room temperature .
  • R suitable protecting , _ ⁇ group or functional group etc.
  • aldehyde group can be located in other positions instead of, for example, the 4-position of piperidine in compound 146 as depicted in Scheme 21. It is to be understood that other heterocycles may also be used besides the ones shown in Scheme 20 and 21.
  • the anions of the methyl-substituted heterocycles may also be reacted with a BOC-pr ⁇ tected piperidone or pyrrolidone (148) to yield alcohols 149 as shown in Scheme 22 (see above reviews on metallations for references) .
  • These alcohols may be reduced using Pt0 2 and TFA (P. E. Peterson and C. Casey, J. Org. Chem. 1964, 29, 2325-9) to yield piperidines and pyrrolidines 150.
  • Pt0 2 and TFA P. E. Peterson and C. Casey, J. Org. Chem. 1964, 29, 2325-9
  • the carbonyl group can be located in other positions instead of, for example, the 4-position of piperidine in compound 148 as depicted in Scheme 22.
  • other heterocycles may also be used besides the ones shown in Scheme 22.
  • R suitable protecting group or functional het group to compounds of by mmeetthhooddss ddee ⁇ scribed previously
  • 3-nitrobenzeneboronic acid (153 : Scheme 24) is commerically available and can undergo Suzuki couplings (Suzuki, A. Pure Appl . Chem. 1991, 63, 419) with a wide variety of substituted iodo- or bromo aryls (aryls such as phenyl, naphthalene, etc.), heterocycles, alkyls, akenyls (Moreno-manas, M. , et al . , J. Org.
  • the carbonyl insertion compounds (158) can also undergo reduction of the carbonyl group to either the CHOH or CH2 linkages by methods already discussed (NaBH 4 or Et 3 SiH, TFA, etc.). These amines can then be converted to isocyanate 5. via the following methods (Nowakowski, J. J Prakt Chem/Chem-Ztg 1996, 338 (7), 667- 671; Knoelker, H.-J.et al . , Angew Chem 1995, 107 (22), 2746-2749; Nowick, J. S.et al., J Org Chem 1996, 61 (11), 3929-3934; Staab, H. A.; Benz, W.
  • protected aminobromobenzenes or triflates or protected ammobromoheterocycles or triflates 159 may undergo Suzuki-type couplings with arylboronic acids or heterocyclic boronic acids (160) .
  • These same bromides or triflates 159 may also undergo Stille-type coupling (Echavarren, A. M. , Stille, J.K. J. Am. Chem. Soc, 1987, 109, 5478-5486) with aryl, vinyl, or heterocyclic stannanes 163.
  • Bromides or triflates 159 may also undergo Negishi-type coupling with other aryl or heterocyclic bromides 164 (Negishi E.
  • Compounds b may be also synthesized by reacting iminoyl chloride c with pyrrolidine/piperidine 1 to yield b where R ⁇ b is not H (Povazanec, F., et al . , J. J. Heterocycl . Chem., 1992, 29, 6, 1507-1512) .
  • Iminoyl chlorides are readily available from the corresponding amide via PCI5 or CCl4/PPh3 (Duncia, J.V. et al . , J. Org. Chem., 1991, 56, 2395-2400) .
  • the urea portion may be in final form or in precursor form.
  • amines are commercially available and can be used as 9_, 10., or used as precursors to isocyanates or isothiocyanates 5.
  • Ketones and trifluoromethylketones undergo reductive amination in the presence of iCl 4 followed by NaCNBH 4 to yield amines (Barney, C.L., Huber, E.W., McCarthy, J.R. Tet. Lett. 1990, 31, 5547-5550) .
  • Aldehydes and ketones undergo reductive amination with Na(AcO) 3 BH as mentioned previously to yield amines (Abdel-Magid, A. F., et al . Tet. Lett. 1990, 31, (39) 5595-5598) .
  • Amines may also be synthesized from aromatic and heterocyclic OH groups (for example, phenols) via the Smiles rearrangement (Weidner, J.J., Peet, N.P. J. Het. Chem., 1997, 34, 1857-1860). Azide and nitrile displacements of halides, tosylates, mesylates, triflates, etc. followed by LAH or other types or reduction methods yield amines. Sodium diformyl amide (Yinglin, H. , Hongwen, H.
  • alkyl chain does not necessarily have to be n- propyl, but that n-propyl was chosen for demonstration purposes only.
  • Deprotection of the phthalimido group with hydrazine yields amine 202.
  • reaction with an isocyanate or via any of the previously described conditions described in Scheme 1 yields urea 203. If an isocyanate is used, the isocyanate can add twice to yield urea-carbamate 204.
  • BOC-l-aminocyclopropane-1- carboxylic acid 216 is coupled to (S)-3-(4- fluorobenzyl ) piperidine using a common amide forming reagent such as BOP, HBTU or HATU to furnish the amide tert-l- ⁇ [ (3S) -3- (4-fluorobenzyl) piperidinyl] carbonyl ⁇ cyclopropylcarbamate (217) .
  • the amide is reduced to the corresponding amine by a reducing agent such as but not limited to BH 3 in THF at room temperature, followed by the removal of BOC protecting group with TFA and neutralization to afford the free amine 218.
  • the free amine is then condensed with an isocyanate or a carbamate to yield the desired urea 219.
  • Part B Preparaton of 4-benzyl-l- (3-amino-n-prop-l- yl) piperidine
  • the reaction Upon cooling to 23 °C, the reaction was poured into aqueous hydrogen chloride (0.20 N, 100 mL) and diethyl ether (75 L) . The layers were separated and the aqueous layer was basified with saturated aqueous sodium bicarbonate to pH 9. The aqueous layer was extracted with diethyl ether (4 x 75 mL) , and the combined organic layers were dried over sodium sulfate.
  • phenylmagnesium chloride (2.0 M, 14.0 mL, 28 mmol, 1 eq) was syringed in slowly and the contents allowed to slowly warm to room temperature and then stirred for 48 h.
  • the reaction was worked up by adding 0.1 N NaOH and EtOAc (200 mL each) .
  • the viscous magnesium salts were suction filtered through fiberglass filter paper. The layers were separated and the aqueous layer was extracted again with ethyl acetate (2 x 200 mL) .
  • Part B Preparation of 2-benzyloxycarbonylamino-1-phenyl- 3 , 4-epoxy-butane .
  • Part C Preparation of 2-benzyloxycarbonylamino-4-[4- (4- fluorophenyl) ethyl-1-piperidinyl] -l-phenyl-butan-3-ol.
  • Part D Preparation of 2-amino-4- [4- (4-fluorophenyl)methyl- 1-piperidinyl] -1-phenyl-butan-3-ol .
  • the material was found to have a purity of greater than 95% and was used directly in the next step without further purification.
  • N-Methyl-4-nitro-benzamide (2.25 g, 12.5 mmol, 1 eq.) and PC1 5 (2.60 g, 12.5 mmol, 1 eq. ) were melted together under house vacuum connected to a NaOH trap behind a safety shield. Melting occurred at 100°C. Heated at 130 °C for 1 hour then purified by kugelrohr distillation at 0.1 mmHg at 130°C. CAUTION: THE EXPLOSIVE PROPERTIES OF THIS COMPOUND ARE UNKNOWN). The iminoyl chloride (12.5 mmol 1 eq. ) in DMF 10 ml was added to NaN 3 in 10 ml of DMF at 25°C and stirred overnight.
  • **A11 compounds are amorphous unless otherwise indicted.
  • **A11 compounds are amorphous unless otherwise indicted.
  • the compounds of the present invention in which E contains ring A can be prepared in a number of ways well known to one skilled in the art of organic synthesis.
  • the nitro group of 166 is then reduced using catalytic hydrogenation to give the corresponding aniline 167.
  • the aniline can be converted to the carbamate 168 using chloro-phenyl formate.
  • the carbamate 168 can then be reacted with various amines to give the urea 169.
  • the aniline 167 can be reacted with the appropriate isocyanates to give the urea 169 directly.
  • the saturated ring analogs can also be used.
  • 4- benzyl piperidine can be alkylated with the urea mesylate 185 (Scheme 30) to give corresponding cyclohexyl derivative 186.
  • 4-benzyl piperidine can also be N-alkylated with the phenacyl bromide 170 to give the nitro ketone 171.
  • the nitro group of 171 is then reduced using catalytic hydrogenation to give the corresponding aniline 172.
  • the aniline 172 can be reacted with the appropriate isocyanates to give the ketone urea 173.
  • the ketone of 173 can be reduced with NaBH to give the alcohol 174.
  • the aniline 176 may be treated with various isocyanates to give the urea alcohols 174.
  • the 4-benzyl piperidine can also be N-alkylated with 3-cyanobenzyl bromide (177 , Scheme 28) to give the cyano analog 178.
  • the cyano group is reduced using Raney nickel to give the corresponding benzyl amine 179.
  • Treatment of 179 with isocyanates gives the urea 180.
  • the saturated ring analogs can also be synthesized using analogous procedures as outlined in Schemes 30 and 31.
  • 4-benzyl piperidine can be alkylated with the urea mesylate 185 (Scheme 29) to give corresponding cyclohexyl derivative 186.
  • the enantiomerically pure amino alcohol 187 [J. Am . Chem. Soc. 1996, 118, 5502-5503 and references therein] one can protect the nitrogen to give the N-Cbz alcohol 188. Swern oxidation of the alcohol gives the aldehyde 189.
  • Reductive amination with piperidine analogs gives the cyclohexyl methyl-1-piperidinyl analogue 190.
  • the Cbz group is removed by catalytic hydrogenation to give the free amine 191, which is treated with a phenylisocyanate to give the desired urea analogue 192.
  • Several examples using these synthetic methods are listed in Table 3a and Table 3.1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente demande porte sur des modulateurs de CCR3 de la formule (I), ou sur des formes de sels de ceux-ci acceptables d'un point de vue pharmaceutique, ces modulateurs étant utiles dans la prévention de l'asthme et autres maladies allergiques.
PCT/US2001/019745 2000-06-21 2001-06-20 N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine WO2001098269A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001271357A AU2001271357A1 (en) 2000-06-21 2001-06-20 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP01950358A EP1363881A2 (fr) 2000-06-21 2001-06-20 N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine
JP2002504225A JP2004517803A (ja) 2000-06-21 2001-06-20 ケモカイン受容体活性調節剤としてのｎ−ウレイドアルキル−ピペリジン
CA002413274A CA2413274A1 (fr) 2000-06-21 2001-06-20 N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21305100P 2000-06-21 2000-06-21
US60/213,051 2000-06-21
US09/598,821 US6605623B1 (en) 1998-12-18 2000-06-21 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US09/598,821 2000-06-21

Publications (2)

Publication Number Publication Date
WO2001098269A2 true WO2001098269A2 (fr) 2001-12-27
WO2001098269A3 WO2001098269A3 (fr) 2003-07-10

Family

ID=26907725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019745 WO2001098269A2 (fr) 2000-06-21 2001-06-20 N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine

Country Status (5)

Country Link
EP (1) EP1363881A2 (fr)
JP (1) JP2004517803A (fr)
AU (1) AU2001271357A1 (fr)
CA (1) CA2413274A1 (fr)
WO (1) WO2001098269A2 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005048932A2 (fr) 2003-11-13 2005-06-02 Bristol-Myers Squibb Company Composes de n-ureidoalkyl-amino en tant que modulateurs de l'activite de recepteurs de la chimiokine
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
US6974869B2 (en) 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
JP2006505494A (ja) * 2002-02-20 2006-02-16 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害する縮合アザ二環式化合物
JP2007506692A (ja) * 2003-09-26 2007-03-22 アクテリオン　ファマシューティカルズ　リミテッド 新規なピリジン誘導体
JP2007519680A (ja) * 2004-01-30 2007-07-19 ノバルティス アクチエンゲゼルシャフト Ｃｃｒ受容体アンタゴニストとして作用するピロリジン誘導体
US7709500B2 (en) 2002-02-18 2010-05-04 Astrazeneca Ab Chemical compounds
JP2010265278A (ja) * 2003-09-15 2010-11-25 Novartis Ag 炎症性およびアレルギー性疾患の処置における、ｃｃｒ−３受容体アンタゴニストとして使用するための１，３−二置換アゼチジン誘導体
US7956070B2 (en) 2004-02-02 2011-06-07 Astrazeneca Ab Piperidines as chemokine modulators (CCR)
AU2011253934B2 (en) * 2004-06-17 2012-11-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
US8445495B2 (en) 2005-12-15 2013-05-21 Cytokinetics, Inc. Certain Chemical entities, compositions and methods
US8513257B2 (en) 2004-06-17 2013-08-20 Cytokinetics, Incorporated Ureas and their use in the treatment of heart failure
WO2014060341A1 (fr) * 2012-10-16 2014-04-24 F. Hoffmann-La Roche Ag Composés carbamate substitués et leur utilisation en tant qu'antagonistes du canal potentiel récepteur transitoire (trp)
US9353096B2 (en) 2012-10-12 2016-05-31 Hoffmann-La Roche Inc. Substituted phenylcarbamate compounds
US9388172B2 (en) 2012-11-08 2016-07-12 Hoffmann-La Roche Inc. Substituted carbamate compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2993897A (en) * 1961-07-25 S-triazinylmethyl ureas
DE2614189A1 (de) * 1976-04-02 1977-10-20 Hoechst Ag Therapeutisch wirksame ureido- und semicarbazido-derivate des tiazols und verfahren zu ihrer herstellung
JP3419539B2 (ja) * 1993-02-17 2003-06-23 中外製薬株式会社 インドリン−２−オン誘導体
WO1997024325A1 (fr) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DERIVES DE DIPHENYLMETHANE UTILISES COMME ANTAGONISTES DU RECEPTEUR MIP-1α/RANTES
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974869B2 (en) 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
US7514430B2 (en) 2001-09-18 2009-04-07 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
US7709500B2 (en) 2002-02-18 2010-05-04 Astrazeneca Ab Chemical compounds
JP2006505494A (ja) * 2002-02-20 2006-02-16 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害する縮合アザ二環式化合物
JP2011026326A (ja) * 2002-02-20 2011-02-10 Abbott Lab バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害する縮合アザ二環式化合物
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
JP2010265278A (ja) * 2003-09-15 2010-11-25 Novartis Ag 炎症性およびアレルギー性疾患の処置における、ｃｃｒ−３受容体アンタゴニストとして使用するための１，３−二置換アゼチジン誘導体
JP2007506692A (ja) * 2003-09-26 2007-03-22 アクテリオン　ファマシューティカルズ　リミテッド 新規なピリジン誘導体
JP4851328B2 (ja) * 2003-09-26 2012-01-11 アクテリオン ファーマシューティカルズ リミテッド 新規なピリジン誘導体
WO2005048932A2 (fr) 2003-11-13 2005-06-02 Bristol-Myers Squibb Company Composes de n-ureidoalkyl-amino en tant que modulateurs de l'activite de recepteurs de la chimiokine
JP2007519680A (ja) * 2004-01-30 2007-07-19 ノバルティス アクチエンゲゼルシャフト Ｃｃｒ受容体アンタゴニストとして作用するピロリジン誘導体
US7956070B2 (en) 2004-02-02 2011-06-07 Astrazeneca Ab Piperidines as chemokine modulators (CCR)
US8513257B2 (en) 2004-06-17 2013-08-20 Cytokinetics, Incorporated Ureas and their use in the treatment of heart failure
US10385023B2 (en) 2004-06-17 2019-08-20 Cytokinetics, Inc. Compounds, compositions and methods
AU2011253934B2 (en) * 2004-06-17 2012-11-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
AU2011253934C1 (en) * 2004-06-17 2013-08-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
US12264133B2 (en) 2004-06-17 2025-04-01 Cytokinetics, Incorporated Compounds, compositions and methods
US8871769B2 (en) 2004-06-17 2014-10-28 Cytokinetics, Inc. Ureas and their use in the treatment of heart failure
US9150564B2 (en) 2004-06-17 2015-10-06 Cytokinetics, Inc. Compounds, compositions and methods
US10975034B2 (en) 2004-06-17 2021-04-13 Cytokinetics, Inc. Compounds, compositions and methods
US9643925B2 (en) 2004-06-17 2017-05-09 Cytokinetics, Incorporated Compounds, compositions and methods
US10035770B2 (en) 2004-06-17 2018-07-31 Cytokinetics, Incorporated Compounds, compositions and methods
US8871768B2 (en) 2005-12-15 2014-10-28 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US8445495B2 (en) 2005-12-15 2013-05-21 Cytokinetics, Inc. Certain Chemical entities, compositions and methods
US9353096B2 (en) 2012-10-12 2016-05-31 Hoffmann-La Roche Inc. Substituted phenylcarbamate compounds
CN104703970A (zh) * 2012-10-16 2015-06-10 霍夫曼-拉罗奇有限公司 取代的氨基甲酸酯化合物及其作为瞬时型感受器电位(trp)通道拮抗剂的用途
WO2014060341A1 (fr) * 2012-10-16 2014-04-24 F. Hoffmann-La Roche Ag Composés carbamate substitués et leur utilisation en tant qu'antagonistes du canal potentiel récepteur transitoire (trp)
US9388172B2 (en) 2012-11-08 2016-07-12 Hoffmann-La Roche Inc. Substituted carbamate compounds

Also Published As

Publication number Publication date
CA2413274A1 (fr) 2001-12-27
JP2004517803A (ja) 2004-06-17
WO2001098269A3 (fr) 2003-07-10
EP1363881A2 (fr) 2003-11-26
AU2001271357A1 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
EP1158980B1 (fr) N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
US6780857B2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6444686B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6331541B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6525069B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000035449A1 (fr) N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
EP1140086A1 (fr) N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
US6605623B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2001098270A2 (fr) N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine
EP1363881A2 (fr) N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine
US6897234B2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2001271359A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
MXPA01006148A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2413274

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 504225

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001271357

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001950358

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001950358

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001950358

Country of ref document: EP